Drug, bio-affecting and body treating compositions inventions 02/06

20060039856 - Magnetic resonance with stimulation: This invention involves blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI) using external stimuli. Different colors of light can be used as the stimulus to assess differential BOLD response to diagnose neurological disorders (e.g., Parkinson's disease, attention deficit disorder, schizophrenia, and substance abuse). In addition, very low dose...

20060039855 - Solid phase preparation of 18f-labelled amino acids: A process for the production of an 18F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I): SOLID SUPPORT-LIKER-SO2—O-TRACER (I) with 18F— to produce the labelled tracer of formula (II)....

20060039859 - Blood brain barrier permeation peptides: Novel blood-brain barrier permeant amyloid-targeting peptides and peptide conjugates are described. The peptide conjugates include a radioisotope or other label in a stable complex that translocates across brain capillary endothelial cell monolayers. The labeled peptide conjugate binds to amyloid plaques (Aβ) associated with Alzheimer's disease, and is useful for the...

20060039857 - Methods for diagnosis using anti-cytokine receptor antibodies: Labeled antibodies, antibody fragments or peptides binding to soluble cytokines or cytokine receptors are used to diagnose whether a patient has cancer or an autoimmune disease. In a preferred embodiment, a radiolabelled tag that is chemically bound to a peptide, antibody, or antibody fragment specific for sTNFR-1 and/or sTNFR2 is...

20060039858 - Radiolabeled antibodies and peptides for treatment of tumors: This invention provides methods for imaging and/or treating a tumor in a subject which comprise administering to the subject an amount of a radiolabeled antibody and/or peptide effective to image and/or treat the tumor, where the radiolabeled antibody and/or peptide binds to a cellular component released by dying tumor cells....

20060039860 - Compositions for delivering nucleic acids to cells: Cyclic amidinium containing compounds and their methods of preparation are described. Compositions containing these compounds facilitate delivery of biologically active polymers to cells in vitro and in vivo....

20060039861 - Peptide-based multimeric targeted contrast agents: Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents....

20060039862 - Identification and use of growth hormone secretagogue receptor type 1a antagonists: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake....

20060039863 - Use of cyanine dyes for the diagnosis of disease associated with angiogenesis: This invention relates to the use of conjugates of cyanine dyes with an angiogenesis specific binding component preferably with an EB-D fibronectin specific binding component for the diagnosis of micrometastasis and small proliferative lesions, in particular primary tumors, precancerosis, dysplasia, metaplasia, inflammatory lesions, e.g. psoriasis, psoriatic arthritis and/or rheumatoid arthritis,...

20060039864 - Abuse-proofed oral dosage form: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, characterised in that it comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally...

20060039865 - Pharmaceutical compositions and methods for the prevention of drug misuse: A pharmaceutical composition including a therapeutic does of an active ingredient susceptible of either intentional or accidental misuse by over-utilization and a sub-therapeutic dose of a compound in an amount sufficient to elicit an undesirable response if the recommended therapeutic dose of the active ingredient is exceeded. A multiple dose...

20060039868 - Inhalable powder containing tiotropium: The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma....

20060039866 - Method for treating sleep-related breathing disorders: Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include mirtazapine in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as...

20060039867 - Method for treating sleep-related breathing disorders with setiptiline: Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include setiptiline in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as...

20060039869 - Intranasal delivery of antipsychotic drugs: An intranasal drug product is provided including an antipsychotic drug, such as haloperidol, in sprayable solution in an intranasal metered dose sprayer. Also provided is a method of administering an antipsychotic drug, such as haloperidol, to a patient, including the step of delivering an effective amount of the antipsychotic drug...

20060039871 - Nasal pharmaceutical formulations and methods of using the same: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific...

20060039870 - Pulmonary delivery of enzymatic medical countermeasures: The present invention provides for non-invasive treatment of nerve agent poisoning by administering nerve agent neutralizing enzymes to the pulmonary epithelium of a subject, by inhalation, where they accumulate within the lungs. Localization of such enzymes in the pulmonary epithelium results in neutralization of the nerve agents at the lungs....

20060039872 - Layered chewing gum tablet: The invention relates to a layered chewing gum tablet comprising at least one layer containing gum base, wherein the at least one layer containing gum base comprises gum base in an amount of 35.5 to 86.5 weight-% based on the total weight of the layered chewing gum tablet and the...

20060039873 - Heavenly mouth wash: Heavenly mouthwash has three natural ingredients. The first is one-third cup apple-cider vinegar, next is two-thirds cup water and last is one tablespoon grated lemon rind. When using the Heavenly mouthwash, you should first gargle with mouthwash for one minute to loosen scum on teeth and tongue, then use tongue...

20060039874 - Teeth whitening device: A device is provided which includes a cavity containing teeth whitening gel. The device can be attached to a tooth so that the tooth lies inside the cavity and the teeth whitening gel comes in contact with the tooth. The device may includes a plurality of sections, each of which...

20060039875 - Ultraviolet light screening compositions: A UV screening composition comprising particles which are capable of absorbing UV light so that electrons and positively charged holes are formed within the particles, characterised in that the particles are adapted to minimise migration to the surface of the particles of the electrons and/or the positively charged holes when...

20060039876 - Compositions to be applied to the skin and the integuments: The present disclosure relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one composite pigment comprising an inorganic core at least partially coated with at least one organic coloring substance, wherein the color parameter Δa*b*pigment of the at least one organic coloring substance is greater than...

20060039877 - Soft solid compositions with reduced syneresis: A soft solid antiperspirant and/or deodorant composition comprising a volatile silicone and a behenamidoalkyl dialkylamine fatty acid as a gelling agent for the volatile silicone....

20060039878 - Hair treatment compositions containing xanthine and alpha hydroxy acid: The invention provides a hair treatment composition such as a shampoo or conditioner suitable for topical application in style hair and in particular to lengthening the hair. The composition comprises an α-hydroxy acid and/or its salt and a xanthine preferably having the following formula....

20060039879 - Use of particular polyols for preventing the hair from breaking, composition comprising them and cosmetic hair treatment process: e

20060039881 - Compositions comprising at least one organic polymer and a mixture of volatile and nonvolatile solvents: Compositions, for example cosmetic compositions, comprising at least one organic polymer, such as a crosslinked organosoluble polymer, and a mixture of at least two solvents, one of which is volatile and incompatible with the polymer, and the other of which is nonvolatile and compatible with the polymer. These compositions...

20060039880 - Make-up composition enabling the make-up of keratin fibers, particularly eyelashes, by droplet deposition: The invention relates to a make-up composition. This composition is characterised in that it comprises a polymer or mixture of polymers selected from the family of hydroxylated polydimethylsiloxanes or non-hydroxylated polydimethylsiloxanes, and of their mixtures, and which has a viscoelasticity and a viscosity which are well determined, in order to...

20060039885 - Liquid skin protective composition: Provided is a liquid skin protective composition capable of protecting the skin from chemical substances in the environment and aqueous irritants such as body fluids, wastes, and exudates, causing less irritation, being applicable easily to the skin, and giving a good skin feel. The liquid skin protective composition contains the...

20060039882 - Hair care agents containing pregelatinized, cross-linked starch derivatives: The invention relates to cosmetic hair care agents that contain either one or more pregelatinized, cross-linked starch derivatives and cationic polymers or one or more pregelatinized, cross-linked starch derivatives and non-ionic, amphoteric and/or anionic polymers....

20060039884 - Baldness related gene and the polypeptide encoded thereby , and uses: The invention has disclosed a baldness-related gene and the encoded polypeptide, and a process for producing the polypeptide by recombinant methods. It has also disclosed the use of Rhor gene and protein in the diagnosis and treatment of baldness....

20060039883 - Biologically active compounds for the modification of bodily odours: The invention relates to the use of MHC ligands, e.g. MHC-binding peptides, for the manufacture of an agent for modifying bodily odours. Particularly, the invention is applicable in the field of cosmetics and medicine....

20060039886 - Self-warming or self-heating cosmetic and dermatological compositions and method of use: This invention relates to cosmetic applications for topical applications to the human skin. In particular, it relates to anhydrous cosmetic and dermatological compositions, with the capacity for self-warming or self-heating upon application. The self-warming or self-heating cosmetic compositions of the present invention comprise: (i) from about 0.1 to about 99%...

20060039887 - Cosmetic or pharmaceutical composition for skin care: The present invention relates to a cosmetic or pharmaceutical composition to reduce skin damage caused by aging and/or the environment. The composition can include a genus Centipeda plant extract, a trace metal source in a skin absorbing form in an amount effective for activating or enhancing superoxide dismutase enzyme, and...

20060039888 - Deodorizing method and apparatus, and a vacuum cleaner using same: An apparatus for deodorizing dust particles includes a housing chamber, a powdering/granulating unit installed in the housing chamber, a deodorant disposed to be movable relative to the powdering/granulating unit, and a driving unit for driving the powdering/granulating unit or the deodorant. The deodorant is formed into granules or powders by...

20060039889 - Anti-fouling cationically crosslinkable varnish compositions and support substrates coated therewith: Silicone compositions particularly useful for the production of anti-fouling varnishes for application to support substrates, these providing an anti-fouling varnish for textiles covered with silicone elastomers which is economical, adhesive, non-slip and glossy; the subject varnishes comprise a crosslinkable silicone composition containing, per 100 parts by weight: 1, at least...

20060039890 - Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant: The present invention features compositions, kits, and methods for treating or reducing a cognitive or psychological disorder, such as depression....

20060039891 - Antineoplastic-dendritic polymer drug delivery system: Antineoplastic dendritic polymer conjugates which are useful drug delivery systems for carrying antineoplastic agents to malignant tumors are prepared. The antineoplastic agent is encapsulated within the dendritic polymer using an ionic charge shunt mechanism, whereby, the antineoplastic agent interacts with the anionic functional groups on the surface of the dendritic...

20060039892 - Methods of healing wounds by administering human il-18: The present invention relates generally to the use of human IL-18, also known as interferon-γ-inducing factor (IGIF), in the treatment of skin wounds, surgical wounds, leg ulcers, diabetic ulcers, gastrointestinal mucositis, oral mucositis, and lung injury....

20060039893 - Adenoviral vectors having a protein ix deletion: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also...

20060039897 - Stinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmet: A stinging cell comprising an exogenous polynucleotide capable of expressing a therapeutic, cosmetic or diagnostic agent in the stinging cell is provided....

20060039894 - Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response: The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ134.5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an immediate-early gene. The present invention also relates to a...

20060039896 - Augmentation and repair of age-related soft tissue defects: The present invention discloses methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or direct surgical...

20060039895 - Ex-vivo rescue of hematopoietic stem cells after lethal irradiation: A method of autologous rescue of an individual exposed to a harmful hematopoietic stem cell condition is described. The method includes removing hematopoietic stem cells from the individual, culturing the hematopoietic stem cells and reintroducing cultured hematopoietic stem cells into the individual. Stem cells are grown in a stromal-cell free...

20060039898 - Method of skin care and/or treatment using rice (oryza sativa) hemoglobin or other hexacoordinated, non-symbiotic plant hemoglobins: Methods for the prevention and treatment of skin damage arising from exposure to nitric oxide and other pollutant oxidizing species, using rice (Oriza sativa) hemoglobin or other plant hexacoordinated, non-symbiotic hemoglobins, in a dermatologically acceptable carrier that can be topically applied to the skin areas, including lips. In some embodiments,...

20060039899 - Animal nutritional product that increases weight gain and reduces diarrhea morbidity, mortality and severity by stimulation of natural immune response, nutritional support of immune function and supplemental nutricines and probiotics: A method of collecting, sterilizing, standardizing, drying and mixing rumen fluid while retaining the activity of the contained bacterial polysaccharides is described. Nutritional compositions including the resulting product, probiotics, nutricines, vitamins, minerals, an amino acid, and a monosaccharide are depicted. The use of this resulting nutritional composition the first few...

20060039902 - Antagonizing interleukin-21 receptor activity: Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid...

20060039901 - Antibodies for inhibiting blood coagulation and methods of use thereof: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor...

20060039904 - Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity: The present invention relates to novel Fc variants that immuno-specifically bind to an Eph receptor. The Fc variants comprise a binding region that immunospecifically binds to an Eph receptor and an Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function....

20060039900 - Epitope directed selection of antibodies to murine tissue factor: A tissue factor antibody which binds to non-human tissue factor and is useful as a surrogate in preclinical testing where the human therapeutic tissue factor candidate antibody does not interact with the homolog target protein in a manner that would provide meaningful information about treatment efficacy or safety....

20060039905 - Galectin 11: The present invention relates to novel galectin 11 proteins which are members of the galectin superfamily. In particular, isolated nucleic acid molecules are provided encoding the human galectin 11 proteins. Galectin 11 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention...

20060039903 - Immunomodulation and effect on cell processes relating to serotonin family receptors: The present invention relates to the discovery that signaling via a serotonin type 1B, 2, 4 and 6 receptor is important in T cell activation such that inhibiting such signaling can be used to modulate the immune response. This immunomodulation is useful for the treatment of immune diseases or conditions,...

20060039906 - Humanized antibodies that sequester abeta peptide: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ....

20060039907 - Method and compositions for treating diseases targeting cd71: Methods and compositions for diagnosing, detecting and treating a pancreatic disease associated with differential expression of CD71 in comparison to healthy cells. Also provided are antagonists or agonists of CD71, and methods for screening agents that modulate the CD71 level or activity in vivo or in vitro....

20060039908 - Transferrin receptor antibodies: The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor....

20060039909 - Human cd28 specific monoclonal antibodies for antigen-non-specific activation of t-lymphocytes: The invention teaches human-compatible monoclonal antibodies which are specific against human CD28 and human T-lymphocytes of several to all subgroups to activate without occupancy of an antigen receptor of the human T-lymphocytes and thus antigen-non-specifically....

20060039911 - Method for the treatment of gastroesophageal reflux disease: A method for the treatment of gastroesophageal reflux disease comprising a combination of active immunization with an anti-gastrin immunogenic composition with an antagonist that blocks or inhibits gastric acid pump activity; or alternatively administering purified anti-gastrin antibodies with an H2 antagonist or proton pump inhibitor of the gastric acid producing...

20060039910 - Methods and compositions for treating allergic inflammation: The invention provides methods and compositions for treating allergic inflammation by combining cytokine antagonists capable of acting synergistically to reduce allergic inflammation in a subject. Methods of in vivo screening for therapeutically effective cytokine antagonists useful for treating allergic inflammation are also provided....

20060039913 - Anti-mcp-1 antibodies, compositions, methods and uses: The present invention relates to at least one novel anti-MCP-1 antibodies, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices....

20060039912 - Antibodies to adipose tissues: A non-therapeutic method of producing antibodies that bind adipose tissues in a target animal in need of the antibodies for modulating the content of adipose tissues in the target animal, the method comprising the steps of (a) preparing an antigen from the adipose tissues of a source animal, (b) administering...

20060039914 - Anti-cancer activity of an anti-thymidine kinase monoclonal antibody: Monoclonal antibodies to thymidine kinase 1 are disclosed which are useful in methods of detecting, diagnosing, and treating cancer....

20060039915 - P-cadherin as a target for anti-cancer therapy: Method of treating or diagnosing cancers involving P-cadherin expression are provided using ligands that target P-cadherin, especially human anti-P-cadherin antibodies. Also provided are screens for identifying anti-P-cadherin antibodies having therapeutic activity....

20060039916 - Method for treating complex regional pain by peripheral administration of a neurotoxin: Methods for treating a non-spasm caused pain by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin....

20060039917 - Method for treating phantom pain by peripheral administration of a neurotoxin: Methods for treating a non-spasm caused pain by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin....

20060039918 - Stress proteins and peptides and methods of use thereof: Provided are HLA pan DR-binding peptides and methods of using such peptides to modulate, block, or inhibit immune responses to effect treatment of immune-mediated diseases and conditions, such as inflammatory and autoimmune diseases, cancer, and microbial infections. These peptides and methods are also useful diagnostically to screen peptide or peptide...

20060039919 - Fusion protein for inhibiting cervical cancer: A fusion protein for inhibiting cervical cancer is disclosed, which comprises a peptide sequence of human papillomavirus type 16, a peptide translocating peptide for translocation, and a peptide within a carboxyl terminal fragment. The present invention further comprising a composition of antibody, which conjugates to E7 peptide, wherein the nucleotide...

20060039921 - Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety....

20060039920 - Orientia tsutsugamushi truncated recombinant outer membrane protein (r47) and (r56) vaccines diagnostics and therapeutics for scrub typhus and hiv infection: A scrub typhus vaccine comprising truncated r47 protein and truncated r56 protein is disclosed. Vaccines composed of r56 protein variants are also disclosed. Methods of reducing HIV viral loads using r47 and r56 proteins and antibodies raised against r47 and r56 are also disclosed....

20060039922 - Streptococcal heat shock proteins of the hsp60 family: Methods and compositions comprising isolated nucleic acid molecules specific to Streptococcus pneumoniae and Streptococcus pyogenes, as well as vector constructs and isolated polypeptides specific to Streptococcus pneumoniae and Streptococcus pyogenes are provided. Such compositions and methods are useful for the diagnosis of Streptococcal infection and for generating an immune response...

20060039923 - Vaccine for preventing and treating porcine progressive atrophic rhinitis: The present invention relates to an animal vaccine directed to progressive atrophic rhinitis (PAR), comprising at least two fragmens of recombinant subunit Pasteurella multocida toxins (rsPMT) capable of eliciting the production of antibodies against Pasteurella multocida associated with PAR, said fragments each having an amino acid sequence that substantially corresponds...

20060039924 - Isolated antibodies crossreactive with peptides used to detect rheumatoid arthritis: The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method...

20060039925 - Mutants of streptococcal toxin a and methods of use: This invention is directed to mutant SPE-A toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-A toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-A toxin. The mutant SPE-A toxins...

20060039926 - Live attenuated coronavirus vaccines: The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo....

20060039927 - Specific binding agents for kshv vil-6 that neutralize a biological activity: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds...

20060039928 - Vaccinia virus host range genes to increase the titer of avipoxviruses: The invention concerns an Avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene. The invention futher relates to cells, preferably avian cells, comprising a Vaccinia virus host range gene or a homologue of said host range gene. Moreover the...

20060039929 - Chimera botulinum toxin type e: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 144) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is...

20060039930 - Methods for enhancing wound healing: A method for treating a patient having a wound is described. The method includes administering an amount of a chemodenervating agent such that healing of the wound is enhanced. The method is illustrated by detailing the mean differences of the scores of the paired experimental and control scars across three...

20060039932 - Application of phytosteroids (and isomers thereof), folic acid, cyanocobalamine and pyridoxine in dietetic (alimentary) fibers: The present invention relates to an Association of chemical agents (namely, phytosteroids (and isomers thereof), folic acids, cyanocobalamine and pyridoxine in dietetic(alimentary) fibers), with intended pharmacological action to prevent the risk of infarction and brain hemorrhage caused by the development of the atherosclerotic process and of the homocysteinemia resulting from...

20060039933 - Method for treatment of insect bites: A method of treating wounds caused by the bites of small insects or jellyfish includes applying a water-based wax emulsion to the wound. When the emulsion dries, it forms a thin, protective film over the wound. Application of the emulsion has been found to provide temporary and immediate relief of...

20060039931 - Stable cream preparations of phenyl-pyridone compounds for topical application: The invention relates to a pharmaceutical cream preparation for topical application in the form of an oil-in-water (o/w) emulsion, containing the following constituents in the lipophilic phase: (i) an optionally substituted 1-phenyl-2-(1H)-pyridone compound or a pharmaceutically acceptable salt thereof, as an active ingredient, (ii) at least one surface-active solubilising agent...

20060039939 - Associative thickeners for aqueous systems: Thiocarbonate compounds which, in one embodiment, are utilized as a rheology modifier or associative thickener. The thiocarbonate compounds thicken or increase the viscosity of a composition, preferably an aqueous composition when used in an effective amount. In one preferred embodiment, the thiocarbonate compounds include at least one hydrophilic group containing...

20060039937 - Composition having antioxidant properties: i

20060039935 - Composition of a transdermal delivery system, which modulates inflammation, via insitu systems, thereby promoting repair of injured, damaged or diseased joints, and soft tissue.: The present invention relates to a composition comprising a mixture of nutritional co-factors synergistically combined and applied as a transdermal surfactant. Said surfactant has the ability to introduce locally, required nutrients that modulate chronic or acute inflammation, thereby promoting the systemic repair of joint and soft tissue damage, with concomitant...

20060039934 - Compositions comprising encapsulated material: A composition such as a water-based consumer product comprises material (e.g. perfume) encapsulated within shell capsules, each capsule comprising an encapsulating wall having an inner surface and an outer surface, with a coating on the inner surface and/or outer surface of the shell wall, the composition further comprising surfactant and/or...

20060039938 - Cosmetic method of caring for greasy skin: The present invention relates to a cosmetic method of caring for greasy skin by topical application to the skin of a composition containing, in a physiologically acceptable medium suitable for topical application to the skin and containing an aqueous phase: (a) porous particles having an average diameter by volume of...

20060039936 - Emulsification system for use in cosmetics: Disclosed are cosmetic compositions containing water, at least one non-polar and/or polar oil, and an emulsification system comprising a polyoxyethylene oxide C12-C24 fatty acid ester; a sucrose fatty acid ester of vegetable origin, and a glyceryl and/or sorbitan C12-C24 fatty acid ester, and methods of making and using the compositions....

20060039943 - Acetyl-coa carboxylase inhibitors for use as pesticides: The present invention relates to the use of inhibitors of the action of eukaryotic-type Acetyl-CoA carboxylase for controlling insect pests. The inhibitors are selected from arylphenoxypropionates and cyclohexanedione oximes, or their mixtures which may be used together with suitable additives, excipients and carriers. The invention further relates to an insecticidal...

20060039942 - Enhanced activity alcohol-based antimicrobial compositions: Antimicrobial compositions which can be used wherever disinfecting compositions are needed, such as in a hospital, healthcare industry, workplace, recreational facility, home or similar environment. The antimicrobial compositions are particularly useful as a topical application for a substrate, such as skin and can be used as a hand sanitizer or...

20060039940 - Novel ester compound and use thereof: It is an object of the present invention to provide a novel ester compound and the use thereof as a sex attractant. The present invention provides a compound represented by formula (I) described below, and a sex attractant comprising, as an active ingredient, the above compound:...

20060039941 - Nucleic acid sequences from drosophila melanogaster that encode proteins essential for viability and uses thereof: Nucleotide sequences are isolated from Drosophila melanogaster that code for proteins essential for viability. These proteins are useful for discovering new insecticides based on the essentiality of the nucleotide sequences for Drosophila viability. Further provided are recombinant proteins and methods for identifying inhibitors to these proteins. Protein inhibitors active in...

20060039944 - Solid polymeric dispersant composition for water-insoluble actives: A solid polymeric dispersant composition for water-insoluble actives includes a primary anionic polymer dispersing agent and a co-dispersant which is a vinyl lactam, in a defined weight ratio, and wettable powders, water dispersible granules and tablets thereof, for delivery of actives to a desired site....

20060039945 - Substrate for volatile delivery systems: Volatile impregnated substrates, such as wicks and mats, that can be used in a dispensing device that uses a heat source or otherwise uses active means to promote the release of the volatile material from the substrate are disclosed. The preferred substrate has a structure including sand particles adhered together...

20060039947 - Biologically active implants: This invention relates to an implant for treating pathological changes in the spinal column and/or locomotor system. According to one embodiment of the invention, the implant has a surface, a body, and an enamel-like or varnish-like coating that is up to 100 μm thick, comprises a biodegradable polymer such as...

20060039946 - Drug eluting medical device: Medical devices configured to be implanted in two or more tissues simultaneously are discussed. A therapeutic agent is disposed on, in, or about at least a portion of an external surface of a medical device configured to be placed in one tissue, but not on, in or about a surface...

20060039949 - Acetabular cup with controlled release of an osteoinductive formulation: An acetabular cup having one or more osteoinductive formulations, wherein each osteoinductive formulation comprises one or more osteoinductive agent(s). In one embodiment of the invention, the acetabular cup comprises a porous coating into which the osteoinductive formulation is impregnated. In another embodiment of the invention, the acetabular cup comprises microchambers...

20060039948 - Implant, therapeutic agent and micelle: The invention relates to an implant, a therapeutic agent, the use of micelles, which are formed from both surfactants as well as active substance molecules, and to a micelle. In order to achieve a defined delivery behavior through pores of a diffusion element, the active substance molecules are covered with...

20060039951 - Inorganic shaped bodies and methods for their production and use: Shaped, preferably porous, inorganic bodies are provided which are prepared from a reactive blend. In accordance with one preferred embodiment, the solution is absorbed into a porous sacrificial substrate such as a cellulose sponge. The solution-saturated substrate is heated and an oxidation-reduction reaction occurs thereby forming an inorganic solid. A...

20060039950 - Multi-functional biocompatible coatings for intravascular devices: A polymeric coating is adapted to substantially eliminate thrombus formation when in contact with blood. The polymeric coating includes a first polymeric layer and a second polymeric layer. Interposed between the first and second polymeric layers is a polymeric matrix layer doped with at least one of a nitric oxide...

20060039952 - Ophthalmic drug delivery device: Ophthalmic drug delivery devices useful for delivery of pharmaceutically active agents to the posterior segment of the eye are disclosed. The devices may include extensions, immobilizing structures, and/or geometries to help properly locate, and prevent migration of, the devices....

20060039953 - Fast dissolving orally consumable films: Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer such as pullulan. Edible films are disclosed that include pullulan and antimicrobially effective amounts of the essential oils thymol, methyl salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs...

20060039954 - Ocular formulations with neuroprotectants to reduce alzheimer and neurotoxic risks created by large zinc dosages: Formulations marketed to elderly consumers for preventing or treating age-related eye diseases such as macular degeneration are modified in various four ways, compared to the formulations tested in the first “Age-Related Eye Disease Study” (AREDS-1) clinical trial. Zinc dosages are substabtially reduced, to reduce the risk of Alzheimer's disease and...

20060039955 - Animal feed compositions with enhanced histidine content: Disclosed are compositions and methods for supplementing ruminant feeds. The compositions include at least one ingredient that has an enhanced histidine content. This ingredient commonly is derived from a non-animal source. The methods include feeding ruminants feed compositions that include the ingredient to improve milk production....

20060039956 - Impregnating solution for cosmetic cloths: The invention relates to preparations for impregnating cosmetic wipes, characterized in that they contain (a) an emulsifier mixture containing nonionic and amphoteric surfactants in a quantity ratio of 10:1 to 1:1, based on the quantity of emulsifiers, (b) a mixture of wax components containing wax esters, partial glycerides and fatty...

20060039958 - Multi-layer films having uniform content: The present invention relates to edible multi-layer films that dissolve in water. In particular, the edible multi-layer films have a first water-soluble film layer and one or more additional water-soluble film layers in at least partial face-to-face engagement with the first film layer. The film layers include a polymer composition...

20060039957 - Multi-layer transmucosal therapeutic system: A film-shaped therapeutic system comprising at least two layers connected with each other, for transmucosal administration of active substances. The system has a layer which is mucoadhesive in an aqueous environment and a mono-layered or multi-layered backing layer. At least one of these layers contains an active substance. The mucoadhesive...

20060039959 - Film-shaped mucoadhesive administration forms for administering cannabis agents: A film-shaped, mucoadhesive administration form having a content of at least one active agent. The active agent is a cannabis agent....

20060039961 - Percutaneous absorption accelerator: The present invention has as an object to provide a composition for external use on skin whose percutaneous absorption of an active component is increased, whereby a large amount of the active component can be delivered into the skin. By employing diglycerol and a low molecular weight betaine together, a...

20060039960 - Plaster containing fentanyl: The invention relates to a transdermal, therapeutic system comprising a coating layer and an adhesive matrix having a fentanyl content....

20060039962 - Amphiphilic compounds and vesicles liposomes for organ-specified drug targeting: An amphiphilic compound is provided capable of forming vesicles or liposomes, said amphiphilic compound having at least one headgroup containing a selectively cleavable group or moiety such as a residue of a choline or phenylalanine derivative, and at least one hydrogen-bonding group located either within said headgroup and/or in close...

20060039965 - Drug delivery system for hydrophobic drugs: Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Such microaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions...

20060039963 - Lipid-analogo phosphoric acid triesters: The present invention relates to novel phosphoric triesters which comprise apolar lipid structures....

20060039964 - Micelle assemblies: The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. Also, the invention encompasses compounds of the formula: A-X-Y-Z-R1 wherein A is a carboxy group or is absent; X is a polyol, Y is —C(═O)—, —C(═S)—, or is absent; Z is O,...

20060039966 - Dosage delivery apparatus for improving user acceptance of oral supplements and medicaments and methods for manufacturing same: Disclosed herein are methods for improving user acceptance of an oral dosage form containing an active ingredient for use as a supplement and/or medicament by masking undesirous flavors, odors, tastes, smells, and/or palatability associated with certain active ingredients. A user may be a human and/or animal in need of a...

20060039967 - Amino acid-containing chewable: The present invention provides a chewable tablet having an improved oral disintegration property, which is easily chewed and capable of containing a large amount of an amino acid depending on need, more specifically, a chewable tablet comprising an amino acid and an oral disintegration promoting agent....

20060039969 - Extended release formulations of erythromycin derivatives: Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cmax in the plasma than an immediate release composition of the erythromycin...

20060039968 - Gabapentin tablets and method for their preparation: The present invention is generally directed to methods for preparing stable gabapentin tablets by wet granulation. A wet granulation method for preparing gabapentin tablets includes forming a mixture by dry mixing of a first portion of a binder with the gabapentin, one or more excipients, or a combination of the...

20060039970 - Tamper-resistant oral opioid agonist formulations: Controlled-release dosage forms comprising opioid agonist and opioid antagonist are provided. The dosage forms release the opioid antagonist and the opioid agonist in a controlled-release manner. The dosage forms may be used to provide pain relief to patients while reducing the side effects associated with opioid agonists....

20060039972 - Effervescent composition including a grape-derived component: The invention features an effervescent composition that includes at least one grape-derived component, at least one effervescent agent, and optionally at least one active agent, where the sum of the weight of the grape-derived component and the weight of the active agent constitute at least about 10% by weight of...

20060039971 - Effervescent composition including alternative hormone replacement therapy agent: An effervescent composition including at least 0.5% by weight of an herbal extract selected from the group consisting of red clover extract, black cohosh extract, sage extract and combinations thereof, at least 0.1% by weight of soy isoflavones, at least 0.1 % by weight of N-acetyl-L-cysteine, and an effervescent agent...

20060039973 - Effervescent composition including water soluble dietary fiber: An effervescent composition that includes granulated water soluble dietary fiber comprising branched oligosaccharide including no greater than 10 sugar units, and an effervescent couple including acid and base....

20060039975 - Paroxetine formulations: Paroxetine is a drug used to treat psychiatric problems such as depression. Controlled release dosage forms comprising release-retarding materials other than hydroxypropyl methylcellulose are described. Also described are methods of wet granulating controlled release paroxetine dosage forms....

20060039974 - Sustained release preparation: The sustained-release preparation of the present invention, which contains a dipeptidyl peptidase IV inhibitor and a hydrophilic polymer, can appropriately inhibit the DPP-IV activity, and is superior in convenience or compliance....

20060039976 - Controlled release composition using transition coating, and method of preparing same: The present invention is concerned with the use of transition coating and transition coating composition to control and or target the release of active pharmaceutical ingredients, and biological, chemical, neutraceutical, agricultural and nutritional materials and a method of preparing controlled release systems utilizing these components....

20060039977 - Oral drug delivery system: There is disclosed an oral delivery system, which comprises: a sachet at least partially formed from at least one microporous permeable membrane, and defining a cavity; a physiologically active substance dissolved or dispersed in a liquid or gel, within the cavity, the microporous or permeable membrane being in contact with...

20060039978 - Self-forming phospholipidic gels: A phospholipid gel is spontaneously formed when combining a first phospholipid, a second phospholipid, and water, wherein the first phospholipid is a neutral phospholipid and the second phospholipid is a negatively charged phospholipid. The first and second phospholipids are of natural origin, semi-synthetic origin, or synthetic origin. Preferably, they are...

20060039979 - Drug delivery system using subconjunctival depot: The present invention provides a drug delivery system to a posterior segment wherein a pharmaceutical composition comprising a drug and a vehicle is administered subconjunctivally to form a depot out of the vehicle, and thereby the drug is gradually released from the depot to enable an effective concentration of the...

20060039980 - Process of preparing a biodegradable polymer using an enzyme catalyst and a biodegradable polymer prepared through the process: Disclosed is a process of preparing a biodegradable polymer using an enzyme catalyst and a biodegradable polymer prepared through the process. The process includes polycondensing a polyhydric alcohol monomer having a secondary hydroxyl functional group and an acid monomer having a dicarboxylic group in the presence of the enzyme catalyst....

20060039982 - Gel materials, medical articles, and methods: A gel material and medical articles including such material, wherein the transparent gel material includes a polymerized poly(alkylene oxide) macromonomer that, prior to polymerization, is free-radically polymerizable, multifunctional (preferably difunctional), and has an average molecular weight of at least about 2000....

20060039981 - Taste masked dosage forms and processes for their preparation: The invention relates to taste masked dosage forms utilizing low amounts of taste masking polymer, and simple and economical processes for the preparation of the taste masked dosage forms. The taste-masked dosage form includes one or more drugs and one or more cationic polymers synthesized from dimethylaminoethyl methacrylate and neutral...

20060039988 - Azithromycin dosage forms with reduced side effects: The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes...

20060039986 - Functional material, process for producing functional material and functional member and environment modifying apparatus using the functional material: A functional material of the present invention is characterized in that it has: a loading component selected from functional components comprising the group consisting of catechins, vitamins, tannins, natural moisturizing factors and essential oils being derived from plants; and a functional ingredient being constituted of an organic polymer material in...

20060039987 - Method and apparatus for producing dry particles: Method and apparatus for producing dry particles. Two liquid components are combined in a static mixer, atomized into droplets, and the droplets dried to form dry particles. Use of the static mixer enables incompatible liquid components to be rapidly and homogeneously combined. The present invention optimizes process conditions for increasing...

20060039985 - Methotrexate compositions: A powder containing methotrexate particles in liquid crystal form suitable for inhalation....

20060039983 - Nanoparticles from supercritical fluid antisolvent process using particle growth and agglomeration retardants: The present invention provides a method of forming particles using supercritical fluid (SCF). In accordance with the method, one or more growth retardant compounds having both SCF-philic and SCF-phobic groups are present when one or more solute materials reach a supersaturation point and begin to form particle nuclei. The growth...

20060039984 - Process for producing fine porous polyimide particle: A method for preparation of porous polyimide microparticles comprising, forming polyamide acid microparticles by pouring polymer solution prepared by dissolving polyamide acid containing 0.5 to 80 weight % of alkali metal salt to polyamide acid by 0.1 to 15 weight % concentration into a poor solvent selected from the group...

20060039989 - Pharmaceutical compositions of cell lysate and processes for the production and use thereof: The present invention relates to a pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s). The pharmaceutical composition of the present invention comprising the cell lysate is in the form of a solution or a suspension or a lyophilisate, in particular, the homogenized cell...

20060039991 - Biological tissue regenerative agent and method for preparing and using same: A biological tissue regenerative agent and method for preparing the same. The agent comprises the compounds that are usually found sequestered within platelets, along with platelet cytosolic components, and serum. The agent is prepared by preparing two quanta of blood. The first is clotted, the cells discarded and the serum...

20060039990 - Biological tissue regenerative agent and method for preparing same: A biological tissue regenerative agent and method for preparing the same. The agent comprises the compounds that are usually found sequestered within platelets, along with platelet cytosolic components, and serum. The agent is prepared by preparing two quanta of blood. The first is clotted, the cells discarded and the serum...

20060039992 - Novel compositions and methods utilizing green-lipped mussel and fatty acids: Disclosed herein are compositions containing synergistic combinations of marine mollusk tissue and at least one fatty acid configured into a delivery formulation suitable for administration to humans and animals. A preferred embodiment of the compositions of the present invention may utilize an extract of green-lipped mussel and at least one...

20060039993 - Retinal cell grafts and instrument for implanting: Surgical instruments, surgical techniques, retinal cell grafts, retinal cell and tissue isolation techniques, and a method for transplanting retinal cells, including photoreceptors, and/or retinal pigment epithelium, with the cells in the isolated tissue having their normal cell to cell configuration are disclosed....

20060039994 - Aluminophosphate-based materials for the treatment of wounds: A method is provided for promoting blood clotting. The area which is bleeding is contacted with an aluminophosphate molecular sieve. The molecular sieve preferably contains a substance which assists the clotting of blood. This substance is preferably Ca2+ ions, which are readily introduced into aluminophosphate molecular sieves. Preferred aluminophosphate molecular...

20060039995 - Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning: Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known...

20060039996 - Method for treating sepsis: Compositions and methods for treating or preventing sepsis in an animal are disclosed. The method comprises administering an electrolyzed saline solution to the animal. In one embodiment, the electrolyzed saline solution comprises ozone and at least one active chlorine species. The electrolyzed saline can further comprise at least one active...

20060039997 - Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations....

20060040000 - Dietary supplement formulation for controlling inflammation and cancer: This invention relates to a dietary supplement which is a phytochemical composition. This composition is capable of controlling inflammatory conditions and preventing and curing cancer in mammals. The composition comprises a synergistic mixture of standardized Boswellia extract, salts of glucosamine, and curcuminoids optionally containing bromelain, chondroitin, methylsulphonylmethane, resveratrol, extracts of...

20060039999 - Pharmaceutical composition for inhibition of tumor growth or metastasis: A pharmaceutical composition for inhibition of tumor growth or metastasis which comprises an effective amount of Phyllanthus urinaria L. extracts, or the combination of the foregoing Phyllanthus urinaria L. extracts and pharmaceutical acceptable carries, adjuvants or excipients....

20060039998 - Remedies: The present invention relates to a therapeutic agent or prophylactic agent for a disease requiring promotion of osteogenesis or enhancement of bone morphogenetic protein production, an agent for promotion of osteogenesis or an agent for enhancement of bone morphogenetic protein production, and a food, beverage or feed for promotion of...

20060040001 - Nutritional compositions and methods for treating or preventing osteoporosis: Disclosed are nutritional compositions and methods of using the compositions for treating or preventing osteoporosis. The compositions comprise (A) those dried fruit solids that inherently comprise flavonoids, hydroxycinnamic acids, and a fiber component of which at least about 20% by weight is soluble fiber, and (B) a soluble, indigestible oligosaccharide...

20060040002 - Anti-itch composition: An anti-itch composition comprising ammonium hydroxide, water, gelatin, a surfactant and menthol essential oils. The composition is a topical antiseptic preparation for neutralizing allergic reactions caused by insect bites, including ants, bees stings, fleas and the like. The composition also provides relief of itching, swelling pain, inflammation and decreases the...

20060040003 - Dietary supplement for supressing appetite, enhancing and extending satiety, improving glycemic control, and stimulant free: This invention relates to a nutritional intervention composition for enhancing satiety prior to a meal and extending satiety after a meal. The nutritional intervention composition decreases food intake producing weight loss over time. The composition consists of Niacin, Vitamin B6, Calcium, Phosphorous, Magnesium, Chromium, Chitosan, Fenugreek, Ginseng, White willow bark,...

20060040004 - Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder: The present invention relates to herbal compositions for the prevention or treatment of disorders of the urogenital system, e.g., urinary incontinence, enuresis (e.g., bed-wetting), benign prostatic hyperplasia, urinary calculi, cystitis, urinary tract infection, and overactive bladder. Specifically, the invention provides compositions that contain C. nurvala and E. arvense and methods...

20060040005 - Anti peptic ulcer activity of an extract of a plant flower woodfordia fruticosa: The present invention provides a pharmaceutical composition comprising an effective amount of an extract or lyophilized extract or at least one bioactive fraction obtained from the plant Woodfordia fruticosa along with one or more pharmaceutically acceptable additives/carriers for treating ulcer caused by the conditions such as stress induced ulcer, peptic...

20060034758 - Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof: One aspect of the invention relates to complexes of a radionuclide with various heteroaryl ligands, e.g., imidazolyl and pyridyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to imidazolyl and pyridyl ligands that form a portion of...

20060034759 - Production and use of novel peptide-based agents with bispecific antibodies: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable...

20060034760 - Radiopharmaceutical formulations: Radiopharmaceutical compounds are disclosed having a radionuclide chelating moiety and a targeting ligand, and optionally a linker. Formulations of compositions useful for making the radiopharmaceutical compounds contain a chelating ligand, a reducing agent, an exchange ligand and a stabilizer....

20060034761 - Heat shock protein as a targeting agent for endothelium-specific in vivo transduction: The present invention relates to the use of Heat Shock Proteins and fragments thereof as targeting ligand. The Heat Shock Protein may be labeled with imaging agents that are capable of binding lectin-like oxidized low-density lipoprotein (LOX-1) or may be attached to a therapeutic agent. The sequences are useful for...

20060034762 - Method for measuring skin absorbability: A method for measuring skin absorbability of a substance, which includes measuring the amount of the substance which is penetrated into hair follicles; and using the resultant data as an index representing the amount of the substance which is absorbed through skin pores, to thereby determine the amount of the...

20060034764 - Fusion proteins of mycobacterium tuberculosis antigens and their uses: The present invention relates to fusion proteins containing at least two Mycobacterium tuberculosis antigens. In particular, it relates to bi-fusion proteins which contain two individual M. tuberculosis antigens, tri-fusion proteins which contain three M. tuberculosis antigens, tetra-fusion proteins which contain four M. tuberculosis antigens, and penta-fusion proteins which contain five...

20060034763 - Therapeutic use of resveratrol for hyperglycemia: The resveratrol, an antioxidant found in various fruits, vegetables, grapes, and red wines, has been shown to have free radical scavenging, anti-inflammatory and anti-thrombogenic activities in the biological systems. Moreover, resveratrol has also been shown to be a good cancer preventive chemical and has been recommended as a food supplement...

20060034765 - Mri method for measuring tumor hemodynamic parameters in the presence of contrast agent extravasation: One or two sets of time course NMR data are acquired using an EPI pulse sequence in which either or both gradient recalled echo NMR signals and spin-echo NMR signals are acquired after bolus injection of a contrast agent. T2* relaxation rates for GE and T2 relaxation rates for SE...

20060034774 - Galactopyrannosyltriaminetetracarboxylate as ligands for bioactivated paramagnetic metal complexes: The present invention provides a triaminetetraacetatesaccharide coordinating to metal ion to form bioactive metal complexes. The bioactive metal complexes of the present invention can be used as contrast agents for magnetic resonance imaging (MRI)....

20060034773 - Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy: R1 through R5 are as defined in the specification FG, which can be the same or different, are carboxy, —PO3H2 or —RP(O)OH groups, wherein R is hydrogen, or an optionally substituted group selected from C1-C20 alkyl, C3-C10 cycloalkyl, C4-C20 cycloalkylalkyl, aryl, arylalkyl, a group bearing an acidic moiety, and a...

20060034768 - Method and device for molecular imaging with the aid of molecular probe: A method is disclosed for molecular imaging with the aid of a molecular probe, the latter containing a contrast enhancing component that is detectable via X-ray fluorescence radiation emitted thereby. A device contains an X-ray source for radiating with X-radiation an object provided with the molecular probe, as well as...

20060034769 - Radiopaque polymeric stents: Preferred embodiments of the present invention relate to polymeric medical devices, such as stents. More particularly, the polymeric compositions disclosed herein comprise halogen-containing, tyrosine-derived diphenols, optionally in conjunction with other groups, such as dicarboxylic acids and/or poly(alkylene oxide), such that the medical devices made from these polymeric compositions are bioresorbable...

20060034766 - Extracorporeal ultrasonic medical device: Ultrasonic devices for preventing microbubbles and/or microparticles from reaching the brain during a PCI or cardiovascular surgery. Devices 27 and 77 are designed for implantation in the chest cavity and operate in combination with needle vents or other vent systems for removing diverted microbubbles. Systems 77 and 83 are designed...

20060034772 - Composition comprising low density microspheres: Low density microspheres, methods for preparing same, and use of same as contrast agents are described. The microspheres have a void which contains a gas or the vapor of a volatile liquid selected from the group consisting of aliphatic hydrocarbons, chlorofluorocarbons, tetraalkyl silanes and perfluorocarbons....

20060034771 - Ultrasound contrast agents and methods of making and using them: Gas or air filled microbubble suspensions in aqueous phases usable as imaging contrast agents in ultrasonic echography. They contain laminarized surfactants and, optionally, hydrophilic stabilizers. The laminarized surfactants can be in the form of liposomes. The suspensions are obtained by exposing the laminarized surfactants to air or a gas before...

20060034770 - Ultrasound contrast agents and process for the preparation thereof: Injectable aqueous suspension of microbubbles filled with a biocompatible gas and a method of preparation thereof. At least 10% of the total volume of gas contained in the microbubbles is contained in microbububbles with a diameter of 1.5 μm or less. The microbubbles can be obtained by preparing an emulsion...

20060034767 - Targeting and tracking of cells to specific organs and tissues in vivo: The present invention provides a method for tracking and targeting cells in viva. In particular, cells are isolated purified and armed with bispecific antibodies which are directly labeled with a detectable marker, or a second antibody specific for a region of the bispecific antibody is labeled with a detectable marker....

20060034775 - Aerosol formulation for inhalation containing an anticholinergic: e

20060034776 - Inhalable medicaments containing a new anticholinergic, corticosteroids, and betamimetics: wherein X− is an anion with a single negative charge; (b) at least one corticosteroid (2); and (c) at least one betamimetic (3), and the enantiomers, mixtures of the enantiomers, racemates, solvates, hydrates, or physiologically acceptable acid addition salts thereof, processes for preparing them and their use in the treatment...

20060034777 - Safe removal of volatile oxidizable compounds from particles, in particular polymer particles: In a method of removing volatile oxidizable compounds from particles present in a container, a gas stream is continuously introduced into the container, the gas stream takes up the oxidizable compound from the particles in the container and a gas stream laden with the oxidizable compound is discharged from the...

20060034779 - Foamable compositions containing vitamin d3 analogues, processes for preparing same and methods of treatment utilizng same: A pharmaceutical or cosmeceutical foamable composition for topical application of vitamin D3 analogues such as calcipotriene and a process of manufacturing the same is disclosed. A method of treatment of skin and scalp disorders, especially of psoriasis or ear infections, by dispensing vitamin D3 analogues such as calcipotriene in a...

20060034778 - Packaged personal care compositions: A packaged mousse-forming, personal care composition, comprising an aluminium based container with an inner surface coating of a thermosetting resin, wherein the composition comprises an aqueous base and a propellant, wherein the aqueous base comprises 0.16% or less by weight of chloride ions and has a pH of from 5.0...

20060034782 - Biofilm therapy interproximal devices: The present invention discloses and claims various interproximal devices and associated methods for: (a) removing and disrupting interproximally, supragingival and subgingivally the microbiological burden associated with biofilms, (b) controlling biofilm influence among at risk adults on certain systemic chronic diseases including: Type II diabetes, heart disease, atherosclerosis, myocardial infarction and...

20060034780 - Dental compositions and methods: A dental composition comprises a fluorescent whitening agent. The fluorescent whitening agent is most preferably 4,4′-bis(2-sulfostryryl)bipheny) or a salt or other soluble derivative thereof, eg the disordium salt. The composition may also comprise an additional tooth whitening agent. Methods of whitening the teeth are also described....

20060034781 - Peroral preparation for prevention or treatment of atopic dermatatis: In accordance with the present invention, a peroral preparation, food and drink, feed, food additive or feed additive for prevention or treatment of atopic dermatitis comprising hydroxyproline or N-acylated derivative of hydroxyproline or a salt thereof is able to be provided and, particularly, said peroral preparation, food and drink, feed,...

20060034783 - Novel method for treating periodontal disease: A method for treating periodontal disease by first disinfecting the affected part with a bactericidal disinfectant containing ferric ions (Fe3+) and L-ascorbic acid as the principal components and one or more members of the group consisting of sorbic acid, benzoic acid and para-hydroxybenzoic acid esters, and then injecting a preparation...

20060034784 - Oral compositions and systems: The present invention relates to oral compositions, systems and methods of applying oral care compositions to the oral cavity. More specifically, oral compositions having optimized characteristics for application and retention on the oral tissues are provided. Furthermore, systems for applying oral compositions to the oral cavity are provided. A method...

20060034785 - Cosmetic and dermatological light protection formulations: Light protective cosmetic or dermatological preparation, characterized in that it comprises (a) PEG-30 dipolyhydroxystearate, (b) 2-ethylhexyl 2-cyano-3,3-diphenylacrylate, (c) at least one dibenzoylmethane derivative and (d) at least 2% by weight of titanium dioxide particles (based on the total weight of the preparation), the preparation being free from water-soluble UV-A filter...

20060034786 - Inhibitors of 15-hydroxyprostaglandin dehydrogenase for stimulating pigmentation of the skin or skin appendages: Inhibitors of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), for example tetrazole, styrylpyrazole, phenylfuran, phenylthiophene, phenylpyrrazole, pyrazolecarboxamide, 2-thioacetamide and azo compounds, are useful for promoting or stimulating pigmentation of the skin and/or skin appendages and/or for preventing and/or for limiting depigmentation and/or whitening of the skin and/or skin appendages, notably for preventing and/or limiting...

20060034787 - Flake-form pigments based on aluminium: The present invention relates to aluminum flakes, comprising (A1) a layer consisting of SiOz, (B) a layer consisting of aluminum on the layer (A1) and (A2) a layer consisting of SiOz on the layer (B), wherein 0.70≦z≦2.0, to a process for the manufacture thereof and to the use thereof in...

20060034788 - Skin cosmetic: There is provided a cosmetic, particularly a skin cosmetic, excellent in imparting transparency (transparent feeling) to the skin, conditioning the skin texture and making wrinkles and hair follicles imperceptible when applied. The cosmetic comprises a powder of porous spherical silica having an average particle size (based on volume) from 3.0...

20060034789 - Malodor counteractant compounds: e

20060034790 - Hair styling composition comprising encapsulated adhesives: Hair styling compositions that comprise at least one encapsulated adhesive, optionally in a cosmetically acceptable carrier, wherein the at least one encapsulated adhesive comprises at least one adhesive encapsulated by at least one encapsulating material. The present invention also relates to methods of providing a holding and/or reshapable effect to...

20060034792 - Cosmetic composition based on a cationic surfactant, an amino silicone or vinyl silicone, a fatty alcohol and a propellant: The present patent application relates to a cosmetic composition, especially a hair composition, wherein it comprises, in a cosmetically acceptable medium, at least one cationic surfactant, at least one silicone chosen from amino silicones and vinyl silicones, at least one fatty alcohol, and at least one propellant....

20060034791 - Cosmetic composition comprising a silicone polymer: The disclosure relates to a make-up and/or care cosmetic composition suitable for application to human skin, lips and/or superficial body growths and exhibiting an improved hold of the color while having a satisfactory or improved gloss, and a satisfactory or improved comfort....

20060034793 - Viscous products for use on the body: Viscous products for use on the body are formulated from a first low viscosity component formulation and a second low viscosity component formulation. The viscous products can be post-foaming and heated upon reacting the first low viscosity component formulation with the second low viscosity component formulation. The viscous products are...

20060034794 - Odor masking substance and method of making: An odor masking substance for masking and eliminating various types of noisome smells and odors, such as those that are produced when dressing field game, is created from a number of types of formulations that include an petrolatum based gel, a glycerine/water gel, a water-in-oil emulsion cream, an oil-in-water emulsion...

20060034795 - Cytostatic drug composition: A drug composition containing as a drug substance a polymeric guanidine derivative based on a diamine containing oxyalkylene chains between two amino groups, with the guanidine derivative representing a product of polycondensation between a guanidine acid addition salt and a diamine containing polyalkylene chains between two amino groups, as well...

20060034796 - Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential: The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified β-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as β-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues...

20060034797 - Polymeric micromulsions: The invention provides novel self-emulsifying diblock copolymers and novel self-emulsifying compositions comprising an active ingredient and a diblock copolymer characterized in that the diblock copolymer is liquid at a temperature below 50° C. and the composition is non-aqueous and liquid at a temperature below 50° C....

20060034798 - Water-in-oil emulsions with ethylene oxide groups, compositions, and methods: Water-in-oil emulsions, compositions, and methods that include a vinyl polymer that includes ethylene oxide-containing side chains and alkyl-Y-containing side chains, wherein Y is O or NR, wherein R is H or CH3, and wherein the alkyl group of the alkyl-Y-containing side chain has at least 4 carbon atoms on average...

20060034799 - Tissue protective cytokines for the protection, restoration, and enhancement fo responsive cells, tissues and organs: Methods and compositions are provided for treating a mammal having inflammation by protecting or enhancing a responsive cell, tissue, organ or body part exhibiting or associated with the inflammation, by systemic or local administration of a composition comprising a tissue protective cytokine. The invention also encompasses combination treatments comprising administering...

20060034800 - Method for treatment of drug addiction and for screening of pharmaceutical agents therefor: The present invention is directed to a method for treatment of drug addiction and screening methods for identifying pharmaceutical agents that ameloriate or prevent the deleterious effects of addition. The invention is as well directed to a group of genes and a group of gene products that are up or...

20060034801 - Method for treating or preventing ischemia reperfusion injury or multi-organ failure: This invention relates to a method for prevention or treatment of ischemia reperfusion injury or multi-organ failure in an individual by administering to said individual an effective amount of an interferon beta....

20060034802 - Procedure for the large-scale t-lymphocytes culture in a homogeneous system: The present invention refers to a procedure for the large-scale amplification of human lymphocytic cell lines for therapeutic use, consisting of a homogeneous culture system. The claimed invention also refers to the production of therapeutic doses of lymphocytic cells cultured homogeneously....

20060034805 - Aav vector compositions and methods for enhanced expression of immunoglobulins using the same: Single AAV vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single...

20060034804 - Adenoviral vectors having a protein ix deletion: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also...

20060034803 - Therapeutic device for osteogenesis: The object of the present invention is to provide an osteogenic treatment device having excellent bone formation ability and being capable of forming bone having a shape corresponding to a shape of site of implantation. The osteogenic treatment device of the present invention includes nucleic acid containing a base sequence...

20060034813 - Expression of proteins in cord blood-derived endothelial cells: The invention provides a population of mature endothelial cells derived from human cord blood. The cells can be transduced with DNA encoding a therapeutically effective protein such as a blood coagulation factor. The cells are useful in a method for the production of a blood coagulation factor. They can further...

20060034811 - Melanoma vaccine and methods of making and using same: An immunotherapeutic vaccine providing antigen presenting cells that have been pulsed with a disrupted cell preparation which includes enucleated cytosol and cell membranes of cancer cells infected with a recombinant vaccinia virus encoding at least one immunostimulating molecule. In a preferred embodiment, the vaccine includes autologous dendritic/monocytic cells (DC/M) that...

20060034812 - Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect: A method for treating tumors. Through infusion or xenotransplantation of xenogeneic cells, such as infusion of murine cells into the peritoneal cavity of humans, a hyperacute rejection response to the cells is induced. This in turn creates a bystander effect to the tumor. This effect creates tumor regression. This treatment...

20060034810 - Novel artificial antigen presenting cells and uses therefor: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of...

20060034814 - Probiotic bacteria: Strains of pro-biotic bacteria, their isolation, characteristics and methods of use to prevent or treat carriage by a food production animal of Salmonella that causes human salmonellosis are provided. Methods for isolating and characterizing the probiotic bacteria are also provided. The present invention further provides methods for using the probiotic...

20060034806 - Trichoderma spp strains with high capactiy of fungus biological control and selection process thereof by molecular markers: Trichoderma spp. strains with high capacity for fungus biological control in wide ranges of temperature and pH are described, such strains being compatible with each other. Likewise, a process of selection of such strains through molecular markers is described. The described process reduce the number of necessary experiments to determine...

20060034808 - Amorphous cell delivery vehicle treated with physical/physicochemical stimuli: Provided are compositions and methods for in vitro generation and in vivo use of tissue for the repair of defective tissue, especially cartilage. Chondrocytes or other cells are cultured in vitro in a biodegradable amorphous carrier within the confines of a space bounded by a semi-permeable membrane with a molecular...

20060034809 - Dry platelet preparation containing stabilized platelets and platelet microparticles as tissue regenerative and non-infusible hemostat: The present invention provides compositions comprising freeze-dried platelets, microparticles, or both for use as a hemostat, such as for treating bleeding or injuries associated with bleeding. It also provides methods of treating injuries or wounds, and methods of causing blood to clot. Likewise, it provides methods of promoting healing of...

20060034807 - Innervated artificial tissues and uses thereof: A three dimensional, innervated artificial tissue comprising a bio-synthetic matrix is provided. The artificial tissue supports cell growth, including surface coverage and three-dimensional cell in-growth, as well as nerve in-growth. Methods of preparing the innervated artificial tissue and methods of innervating artificial tissues or tissue substitutes are also provided. The...

20060034815 - Novel statin pharmaceutical compositions and related methods of treatment: The invention provides novel omega-3 oil solutions of one or more statins. These solutions are readily bioavailable. Notably, because the solutions of the invention contain an omega-3 oil as the major ingredient, they not only provide an antihypercholesterolemic effect due to the statin active ingredient, they also provide recommended daily...

20060034816 - Wound dressings comprising hydrated hydrogels and enzymes: A skin dressing, particularly a wound dressing, comprises oxidoreductase enzyme and, optionally, peroxidase enzyme, wherein the enzyme(s) are present in hydrated condition, e.g. being present in one or more hydrated hydrogels. The dressing is used by being located on the skin of a human or animal e.g. over a wound....

20060034817 - Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase: Histidine ammonia lyase (HAL) isolated from Corynebacteriaceae can decrease serum histidine levels, induce accumulation of urocanic acid, and is not inhibited by L-histidinol. As a result, histidine ammonia lyases similar to the one isolated from Corynebacteriaceae are uniquely suitable for combination therapy with L-histidinol to treat histidine- and/or histamine-dependent pathologies,...

20060034818 - Placental alkaline phosphatase to control diabetes: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may...

20060034819 - Proteins and methods useful for assessing risk of cardiovascular disease: The invention relates to a mutant protein comprising at least a fragment of a mutant dimethylarginine dimethylaminohydrolase (DDAH) enzyme, wherein the fragment possesses an affinity for asymmetric N,N-dimethyl arginine (ADMA) and/or L,N-monomethylarginine (LNMMA), which exists at lower plasma levels than ADMA, and is deficient in hydrolyzing ADMA or LNMMA to...

20060034821 - Methods and compositions for treating neoplasms: The present invention comprises the periodic administration of a solution of neuraminidase to a patient with a neoplasm until the neoplasm has receded. The administration of the solution of neuraminidase can be administered by subcutaneous injection, intramuscular injection, intravenous injection, nasal administration, sublingual administration or transdermal administration. The present invention...

20060034820 - Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis: The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof....

20060034822 - Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vitreous body of the eye: A thimerosal-free hyaluronidase preparation wherein the preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also disclosed is a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of the eye, said method comprising the step of...

20060034823 - Method of production and use of crotoxin as an analgesic: Disclosed a pharmaceutical composition including one of crotoxin, mojavetoxin or a related toxin and a carrier for use in the treatment of chronic pain, especially to the treatment of heretofore intractable pain such as that associated with advanced cancer wherein the treatment is independent of the reduction of tumors. The...

20060034824 - Pharmaceutical composition comprising carriers for products: The present patent application refers to a new product composition comprising: BROMELINE . . . more than 0.01%....

20060034825 - Method and anorectal formulations for treating hemorrhoidal diseases: A method and anorectal formulation for treating a hemorrhoidal disease in a patient suffering therefrom. The method comprises the local administration of a therapeutically effective amount of activated carbon to the anorectal region of a patient. The anorectal formulation comprises a therapeutically effective amount of activated carbon as an active...

20060034831 - Combination therapy for diabetes, obesity and cardiovascular diseases using gdf-8 inhibitors: A method of treating obesity, cardiovascular diseases, and disorders of insulin metabolism in a subject, comprising administering to the subject a therapeutically effective amount of a GDF-8 inhibitor, and a therapeutically effective amount of at least one other therapeutic agent which treats the targeted syndrome....

20060034830 - Immunoglobulins comprising predominantly a galglcnacman5glcnac2 glycoform: The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is GalGlcNAcMan5GlcNAc2....

20060034828 - Immunoglobulins comprising predominantly a glcnacman5glcnac2 glycoform: The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is GlcNAcMan5GlcNAc2....

20060034829 - Immunoglobulins comprising predominantly a man3glcnac2 glycoform: The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Man3GlcNAc2....

20060034827 - Stabilized liquid anti-rsv antibody formulations: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof,...

20060034826 - Use of agents that modulate the interaction between pd-1 and its ligands in the downmodulation of immune responses: Disclosed are methods for downmodulating an immune response comprising contacting all immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1), to thereby modulate the immune response....

20060034832 - Cell death inhibitor: The cell death inhibitor comprising a substance capable of binding to macrophage migration inhibitory factor is useful as a preventive/therapeutic agent for, e.g., heart diseases, neurodegenerative diseases, cerebrovascular diseases, central nervous infections, traumatic diseases, demyelinating diseases, bone/joint diseases, kidney diseases, liver diseases, myelodysplastic diseases, arteriosclerosis, diabetes, pulmonary hypertension, sepsis, inflammatory...

20060034836 - Enhancing the circulating half-life of antibody-based fusion proteins: Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the junction region between the antibody moiety and the fused protein moiety in an antibody-based fusion protein. An antibody-based fusion protein with an altered...

20060034835 - Immunoglobulin variants and uses thereof: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases....

20060034834 - Intrabody-mediated control of immune reactions: The present invention is directed to methods of altering the regulation of the immune system, e.g., by selectively targeting individual or classes of immunomodulatory receptor molecules (IRMs) on cells comprising transducing the cells with an intracellularly expressed antibody, or intrabody, against the IRMs. In a preferred embodiment the intrabody comprises...

20060034833 - Single domain antibodies directed against interferron-gamma and uses therefor: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to interferon gamma. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the IFN-gamma...

20060034837 - Method and agents for the prevention, inhibition and therapy of cancers: Disclosed are uses of Gangliosides GM1 and/or asialo-GM1 substances simulating the carbohydrate portion of said gangliosides with regard to bonding to anti-GM1 antibodies and/or anti-ADM1 antibodies for producing agents which bind or block anti-GM1 antibodies and/or anti-AGM1 antibodies which bond to natural killer cells (NKC) or for blocking antigen-presenting cells...

20060034838 - Anti-human vegf receptor flt-1 monoclonal antibody: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a...

20060034840 - Erbb antagonists for pain therapy: The present application describes the use of ErbB antagonist, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain....

20060034843 - Interaction of smad6 with hox proteins and uses thereof: The present invention describes a novel interaction between Smad6 and the Hox genes in nuclear transcriptional regulation following BMP signal transduction. The present invention further provides methods of using this novel Smad6/Hox protein interaction to regulate gene expression, regulate bone formation and control osteoporosis. Further provided are methods of screening...

20060034841 - Method of depleting regulatory t cell: The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering...

20060034839 - Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor: The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the...

20060034842 - Treatment with anti-erbb2 antibody combinations: The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations....

20060034844 - Stimulation of t cells against self antigens using ctla-4 blocking agents: Stimulation of T cells to respond to self antigens is achieved through a blockade of CTLA-4 signaling. CTLA-4 blocking agents are combined with antigen preparations, either alone or with additional immune response stimulating agents, in costimulation strategies to break immune tolerance and stimulate an enhanced T-cell response against self antigens....

20060034845 - Single domain antibodies directed against tumor necrosis factor alpha and uses therefor: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the...

20060034846 - Use of tf antagonists: Methods of inducing, promoting, and/or enhancing one or more physiological responses associated with the treatment and/or prevention of inflammatory arthritides and/or other inflammation-related conditions in mammals and/or mammalian tissues including delivery of an effective amount of at least one tissue factor antagonist, at least one tissue factor inhibitor, or a...

20060034848 - Methods and compositions for treating alzheimer's disease: The present invention relates to the treatment, diagnosis, and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for reducing or preventing the interaction of β-secretase (BACE) with low density lipoprotein receptor related protein (LRP)....

20060034847 - Methods of treating a subject for a condition: Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods....

20060034849 - Antibodies reactive with beta (1-3)-glucans: Monoclonal antibodies reactive with β(1-3)-glucans are disclosed. More precisely, two monoclonal antibodies, B3B and A10A, reactive with β(1-3)-glucan and/or β(1-3) (1-6)-glucan associated epitopes in free, non-associated form, and/or in cell wall fragments of Candida and Cryptococcus are disclosed. Further, A10A is also reactive with a β(1-6) (1-3)-glucan epitope present on...

20060034850 - Antibodies as t cell receptor mimics, methods of production and uses thereof: The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such...

20060034852 - Taci-immunoglobulin fusion proteins: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors....

20060034851 - Targeted therapeutic delivery of vitamin d compounds: The present invention is directed to a conjugate which includes at least one vitamin D moiety thereof and at least one targeting molecule moiety to pharmaceutical compositions of the conjugate, and to methods for using the conjugate for target-specific delivery of vitamin D or analogs thereof to tissues in need...

20060034853 - Novel human virus causing respiratory tract infection and uses thereof: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as human coronavirus-HKU1 (“HCoV-HKU1”), isolated in Hong Kong. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus of positive polarity. Futher study on nasopharyngeal aspirates from patients with community-acquired...

20060034854 - Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria: The present invention relates to immunogenic compositions and vaccines for the prevention or treatment of Gram negative bacterial infection. Immunogenic compositions of the invention comprise transferrin binding protein and Hsf, and the combination of these two antigens have been shown to act synergistically to produce antibodies with high activity in...

20060034856 - Epha2 antigen t epitopes: The invention concerns peptides constituting T epitopes of EphA antigen, exhibited by MHC I. Said peptides are useful in particular in antitumoral immunotherapy....

20060034855 - Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein: The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AssPP epitope spanning the ss-secretase cleavage site of AssPP and a method for inducing an immune response against the ss-secretase cleavage site of...

20060034857 - Notch: The present invention relates to the use of therapeutic compounds in the modification of T-cell, T-cell antigen presenting cell (APC) interactions and the interactions between pathogenic organisms and immunocompetent cells of a host. In particular it relates to the use of these compounds in the modulation of the interaction between...

20060034858 - Prevention and treatment of amyloidogenic disease: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is...

20060034859 - Naturally processed measles virus peptides eluted from class ii hla molecules: A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more...

20060034860 - Protein-protein interactions in human immunodeficiency virus: The present invention relates to protein-protein interactions involved in AIDS. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs of...

20060034861 - Hcv e1 comprising specific disulfide bridges: The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelope proteins or parts thereof as well as to methods using said HCV E1 envelope proteins...

20060034863 - Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof: The inventors have discovered that a CKβ8-1 truncation variant, CKβ8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CKβ8-1(25-116) is also a functional ligand for...

20060034862 - Method for diagnosing early and late lyme borreliosis: The present invention relates to a method for detecting Borrelia burgdorferi sensu lato infection or the presence of antibodies against Borrelia species in a body fluid from a suspected infected or vaccinated human or other mammal, to a diagnostic kit useful in said method and to an immunoassay method for...

20060034866 - Adipocyte complement related protein homolog zacrp3: The present invention relates to polynucleotide and polypeptide molecules for zacrp3, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. The polypeptides and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention...

20060034864 - Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors: Immunomodulating agents comprising at least one Fc receptor ligand and at least one immunosuppressive factor are provided as are methods for their manufacture and use. The immunomodulating agents may be in the form of polypeptides or chimeric antibodies and preferably incorporate an immunosuppressive factor comprising a T cell receptor antagonist....

20060034865 - Soluble mhc artificial antigen presenting cells: An artificial antigen presenting cell includes a liposome having at least one recombinant soluble MHC-peptide complex incorporated therein. The artificial antigen presenting cell may also include at least one additional signal molecule incorporated therein for manipulating the intensity and quality of the immune response. The recombinant soluble MHC molecule is...

20060034867 - Needle-free administration of felv vaccines: The invention provides a novel method of vaccination of an animal of the felidae family against feline leukemia. The FeLV recombinant vaccine based on viral vector with the aid of a liquid jet needle-free injector can result in distribution of the vaccine essentially in the dermis and the hypodermis of...

20060034868 - Methods and vaccines for providing in ovo protection against turkey rhinotracheitis: Methods and compositions for protecting avian hosts (e.g., turkeys and/or chickens) from turkey rhinotracheitis virus and/or TRT or SHS respiratory distress utilize in ovo administration of live, avirulent strains of TRTV at appropriate dosage levels on a per egg basis to provide an effective and efficient vaccination having acceptable safety...

20060034869 - Drug for treating liver diseases with the use of hollow protein nanoparticles: The invention provides a drug for treating hepatic diseases with the use of hollow protein nanoparticles. The effectiveness of the drug has been proved by animal testing. The invention also provides a therapeutic method using such a drug. In a drug according to the present invention, a substance to be...

20060034870 - Carrier protein having an adjuvant effect, immunogenic complex containing it, process for their preparation, nucleotide sequence and vaccine: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein...

20060034871 - Immunogenic compositions for chlamydia trachomatis: The invention relates to immunogenic compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. The composition may comprise at least two components, one component of which comprises Chlamydia trachomatis antigens for eliciting a Chlamydia trachomatis specific TH1 immune response and another component of which comprises antigens for...

20060034872 - Compositions and methods for preventing abuse of orally administered medications: Disclosed herein is the use of chemical irritants, such as vanilloid receptor-1 agonists, in sustained/controlled release pharmaceutical preparations which also contain a drug typically having high abuse potential. Inclusion of the VR1 agonist in the pharmaceutical preparation interferes with illicit or inappropriate dosing without significantly interfering with the action of...

20060034873 - Palatable suspending vehicle for pharmaceutical ingredients: The invention relates to a liquid vehicle that can be used to create suspensions and/or solutions of liquid or powdered medications. The vehicle is thixotropic and has improved stability and rheologic characteristics. Vehicles of the invention include an aqueous medium and a suspending agent comprising a polysaccharide having at least...

20060034877 - Cationic lotion: Lotion made with saturated sodium chloride water and monohydroxy plus polyhydroxy alcohols to relieve stiffness in skin around knee joints....

20060034874 - Composition for lessening malodors during hair treatment and hair removal and method of use: The use of strontium ions to reduce malodors associated with various chemical hair removal and hair treatment procedures is disclosed. Typical formulations include alkali metal thioglycolate depilatories containing from 0.2% to 2% strontium chloride....

20060034876 - Cosmetic compositions with tapioca: A cosmetic composition is provided which includes tapioca starch, polyacrylic beads, an emulsifier and a cosmetically acceptable carrier. Optionally the composition may include a polysiloxane material to provide an initial silky feel upon skin contact, a fatty acid, a preservative and a polyhydric alcohol....

20060034878 - Iodized oil: Microorganism resistant heavy and light oils with suspended resublimed iodine for dermal protection....

20060034875 - Novel organopolysiloxane polymer, pasty composition, and cosmetic preparation containing the composition: An organopolysiloxane polymer having a glycerol derivative which can swell up by containing at least its own weight of a liquid oil, a pasty composition comprising a liquid oil blended with this polymer, and a cosmetic material containing these polymers or pasty compositions....

20060034879 - Scale-like composite particles and cosmetics with the same blended therein: Scale-like composite particles having oily feel as well as soft and smooth feel are provided. The scale-like composite particles include inorganic oxide particles having an average diameter in a range from 0.1 to 3.0 μm and adhered in a single layer to a surface of resin-coated scale-like inorganic particles. The...

20060034880 - Cleaning and disinfecting composition: The present invention provides a non-cationic antimicrobial agent containing composition which blooms when added to water. The compositions have good cleaning, disinfecting and bloom properties....

20060034881 - Animal bone fiber and method of producing the same: The bones of animals such as bovines and horses are, for example, boiled, dried sufficiently, melted under heating and made into a fibrous or filamentous form to produce animal bone fiber using animal bones as raw material. These animal bones have various effects such as an alkalinizing effect, antibacterial ability...

20060034882 - Yarns and fabrics having long-lasting mosquito repellent or antibacterial effect and their preparation: The subject invention pertains to yarns and fabrics having a long-lasting mosquito repellent or antibacterial effect. The subject invention also pertains to a method of producing yarns and fabrics having a long-lasting mosquito repellent or antibacterial effect....

20060034884 - Coated medical device having an increased coating surface area: The present invention is directed to a coated medical device for delivering a biologically active agent to a body tissue such as a body lumen, said coated medical device having an increased coating surface area for adjusting the release rate of a biologically active agent, such as a drug, from...

20060034883 - Composite stent with polymeric covering and bioactive coating: A composite expandable stent for delivery into a vessel carrying blood comprising an expandable support frame having first and second end portions. A porous imprevious polymer sleeve having inner and outer surfaces extending over the support frame. A coating is disposed on at least one of the inner and outer...

20060034885 - Medical use of aglycon geniposidic acid: The present invention relates to a drug-loaded biodegradable stent and methods for treating vulnerable plaques of a patient comprising a plurality of layers or zones, each layer or zone comprising its own specific biodegradation rate and its specific drug loading characteristics. In one embodiment, the layers and zones are configured...

20060034886 - Bonded fiber structures for use in controlling fluid flow: A flow control element is provided for use in selectively controlling the flow of a liquid through an annular conduit. The flow control element comprises a self-sustaining, three dimensional fibrous element comprising a network of polymeric fibers. These fibers are disposed in a highly dispersed and randomly spaced orientation and...

20060034889 - Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof: A water soluble, biodegradable AB type diblock copolymer which comprises 61 to 85% by weight of a biodegradable, hydrophobic A block comprising a biodegradable polyester, and 15 to 39% by weight of a biocompatible, hydrophilic B block comprising a monofunctional polyethylene glycol(PEG) having a number average molecular weight less than...

20060034888 - Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages: Coatings for an implantable medical device and a method of fabricating thereof are disclosed, the coatings including block-polymers comprising at least one poly(hydroxyacid) or poly(hydroxy-alkanoate) block, at least one block of a biologically compatible polymer and at least one type of linking moiety....

20060034887 - Implantable structure for prolonged and controlled release of an active principle: The invention relates to an implantable structure of flexible consistency for the sustained and controlled release of an active substance, consisting of a bioresorbable support and an active substance, in which the bioresorbable support is formed of a material comprising an aliphatic polyester of therapeutic value as the main component....

20060034891 - Biodegradable controlled release bioactive agent delivery device: The invention provides implantable medical devices that are fabricated, at least in part, from biodegradable polymeric material. The implantable medical devices are used to provide bioactive agent to a treatment site, and are particularly useful for treatment of limited access regions of the body....

20060034892 - Composition for topical administration: The present invention provides a composition for topical administration comprising an interleukin 2 inhibitor and an antimicrobial agent as active ingredients thereof, wherein said interleukin 2 inhibitor contains a tricyclo compound as shown by the general formula (I) or pharmaceutically acceptable salt thereof. The present invention further provides a method...

20060034890 - Device for ocular delivery of active principles by the transpalpebral route: The invention relates to a device for ocular delivery of active principle(s) (1) comprising a first outer layer (2) which is essentially non-leaking, and a second inner layer (3) which has a surface (7) able to come into contact with at least one eyelid. characterized in that the second layer...

20060034896 - Serum remnant-like lipoprotein concentration regulator: The present invention discloses serum remnant-like lipoprotein concentration regulators containing triglyceride of medium-chain fatty acids, wherein 90% or more by weight of the fatty acids as components of the medium-chain triglyceride are saturated fatty acids having 8 and 10 carbon atoms; weight ratio between the saturated fatty acids having 8...

20060034895 - Supplement food for low blood glucose recovery: A supplement food which is useful when the diabetic of recuperation at home lapses into low blood glucose condition, and a supplement food for taking in easily, acting quickly to recovering low blood glucose condition, and, moreover, not having durability after recovery. A supplement food having glucose as the principal...

20060034893 - Use of hesperidin or one of its derivatives for making a medicine for bone formation stimulation: The invention relates to the use of the compound hesperidin or of one of its derivatives for the manufacture of a composition designed to stimulate bone formation and/or inhibit bone resorption in man or animals....

20060034894 - Warming compositions and delivery systems therefor: The present invention includes compositions for imparting a controlled-release warming sensation to the oral receptor areas of a user. The oral, controlled-release warming compositions include a warming agent and a hydrated or swollen food-grade polymer which forms a matrix with the warming agent. Also included are oral delivery systems for...

20060034897 - Delivery system for two or more active components as part of an edible composition: A delivery system for inclusion in an edible composition is formulated to have at least two active components with an encapsulating material for managing the release of the two actives relative to each other when used in an edible composition....

20060034898 - Method for using fifra-exempt substances, materials exhibiting antimicrobial, insecticidal, biocidal and/or odor controlling properties having one or more of these substances coated thereon and/or incorporated therein, and products that are made using the: A method for using FIFRA-exempt substances (e.g., essential oils), materials having one or more such substances coated thereon and/or incorporated therein, and products that are made using these materials, are provided. The properties demonstrated by the inventive materials and products include the control or killing of, for example, decay causing...

20060034901 - Adhesive material and adhesive preparation: The present invention provides an adhesive material to be adhered to the skin etc., which maintains, for a certain time period after adhesion thereof to the skin surface, suitable adhesiveness that does not allow easy peeling or cause irritation to the skin, and which permits, when it is to be...

20060034900 - Adhesive preparation containing fentanyl: The present invention provides a Fentanyl-containing percutaneously absorbable adhesive preparation, which is obtained from economic starting materials, has a constitution simpler than that of conventional ones, has sufficient skin permeability, and which permits control of skin permeability by changing the mixing ratio of two kinds of polyisobutylene having different molecular...

20060034903 - Apparatus and method for transdermal delivery of natriuretic peptides: An apparatus and method for transdermally delivering a natriuretic peptide comprising a delivery system having a microprojection member that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the...

20060034899 - Biologically-active adhesive articles and methods of manufacture: The present invention is a method of coating an adhesive layer. The method includes non-contact depositing a fluid solution onto the adhesive layer and allowing the fluid solution to substantially dry, where the fluid solution comprising a biological active. The fluid solution exhibits a Hildebrand solubility parameter of at least...

20060034902 - Microprojection apparatus and system with low infection potential: A transdermal agent delivery apparatus and system having a low infection potential comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers....

20060034905 - Adhesive composition: An adhesive composition is described which has improved initial tack, long-term adhesion, water uptake and translucency characteristics and may be prepared by melt extrusion. Uses of these compositions are also described, for example, their use as blister pads and wound dressings....

20060034904 - Transdermal delivery using emcapsulated agent activated by ultrasound and or heat: A method for delivery of substance through at least one dermal layer, by providing a substance in microcapsules at a predetermined size, within a medium (150) for holding the microcapsules; placing the medium for holding the microcapsules on a surface of a patch (100) adjacent the skin (320) of a...

20060034908 - Manufacturing process for liposomal preparations: The present invention provides manufacturing processes for liposomal preparations. In accordance with the methods, a lipid fraction is dissolved in a water-miscible organic solvent. This solution comprising the lipid fraction can be added to and mixed with an aqueous solution under conditions to form a bulk liposomal preparation. Desirably, the...

20060034907 - Method of manufacturing pharmaceutical preparations containing liposomes: A method of manufacturing liposome-containing preparations which contain liposomes exhibiting superior stability in vivo and high enclosure rate of a drug is disclosed, comprising mixing a supercritical or subcritical carbon dioxide, one or more liposome membrane constituents including a phospholipid exhibiting a phase transition temperature and a water-soluble chemical....

20060034909 - Protein and peptide delivery to mammalian cells in vitro: Compositions and methods for delivery of proteins and peptides to mammalian cells in vitro are described. Specifically, polypeptide-surfactant complexes formed from noncovalent hydrophobation of polypeptides and reversible hydrophobic modification of polypeptides are described. The compositions can be used to delivery positively charged, negatively charged and charge neutral polypeptides to cells....

20060034906 - Treatment of lung diseases and pre-lung disease conditions: In part, the present invention relates to a method of treating lung diseases and pre-lung disease conditions such as precancerous lesions comprising administering to a patient in need a therapeutic agent comprising lipid composition. The present invention also relates to an inhalation device for administering lipid complexes comprising therapeutic agents....

20060034910 - Pharmaceutical composition for extended release of phenytoin sodium: The present invention provides an oral extended release solid pharmaceutical composition of phenytoin sodium or its pharmaceutically acceptable derivative thereof and the process of manufacturing the same the said extended release oral solid pharmaceutical composition comprising of at least one suitable pharmaceutically acceptable excipient alongwith phenytoin sodium. The said extended...

20060034918 - Buoyant formulations of betaine: An oral control release formulation for releasing at least one betaine after oral administration to a human, said formulation comprising at least one pharmaceutically acceptable means ensuring an at least partial floating of the formulation releasing at least one betaine in the gastro-intestinal tractus....

20060034917 - Coating of tablet cores: A process for the coating of tablet cores, said tablet core comprising an effective amount of at least one pharmaceutically active compound, comprising spraying a coating solution or suspension comprising a sugar, or a starch, or a mixture of a sugar and a starch onto the tablets or tablet cores...

20060034912 - Compositions and methods for nutrition supplementation: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in...

20060034916 - Compositions and methods for nutrition supplementation: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in...

20060034915 - Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor: A formulation of dexamethasone is prepared by preparing a dilute aqueous suspension of dexamethasone in a viscosity increasing excipient such as starch. The suspension is sprayed onto base ingredients and the resultant mixture is dried to provide a granulation of uniform potency....

20060034914 - Direct compression polymer tablet core: The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of...

20060034919 - High ibuprofen content granules and their preparation and their use in pharmaceutical dosage forms: Described are granules composed at least of a substantial amount of ibuprofen, at least one pharmaceutically-acceptable super disintegrant, and at least one pharmaceutically-acceptable binder different from the super disintegrant(s), the super disintegrant(s) being substantially uniformly dispersed throughout the granules. The methods for preparing such granules are described. The granules are...

20060034913 - Multiplex drug delivery device: A capsule or shell for oral administration at the onset of an acute adverse health event (e.g. chest pain). The shell has a plurality of impermeable enclosures in which dosage units are situated. The shell and impermeable enclosures, are made from materials which promptly disintegrate in the buccal, oral, lingual...

20060034911 - New oral immediated release dosage form: The present invention relates to a solid oral immediate release dosage form of a pharmaceutically active compound, N-[(1,2,3,4-tetrahydro-5-methyl-8-(4-methylpiperazin-1-yl)-2-naphthyl]-4-morpholinobenzamide, in the form of the free base or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing said dosage form, the use of said dosage form and a method...

20060034921 - Effervescent bisphosphonate formulation: An effervescent formulation of alendronate contains an acid source, a carbonate source, a binder, a lubricant and optionally, flavoring agents, colorants and sweeteners....

20060034920 - Effervescent formulations of oxytocin: An effervescent formulation comprising oxytocin, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising oxytocin wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the oxytocin....

20060034922 - Controlled release metformin compositions: A method for treating a patient using an antidiabetic drug, said method comprising administering to the patient a high dose of the antidiabetic drug wherein said antidiabetic drug exhibits one or more dose proportional pharmacokinetic parameters is described....

20060034926 - Controlled release system: The invention relates to a system for controlled release of medicinally active substances, which comprises sucrose acetate isobutyrate (SAIB) and a further solvent....

20060034924 - Mesostructured silica/block copolymer monoliths as a controlled release device and methods of manufacture: The invention comprises the design, synthesis, and characterization of mesostructured silica/block copolymer composite monoliths as controlled release systems. The controlled release function is based on the formation of mesostructured silica/block copolymer architectures via surfactant-templated sol-gel processing. Multi-layered or gradient monoliths are produced by layer-by-layer sol-gel processing to provide pulsed and...

20060034923 - Pharmaceutical compositions for controlled release delivery of biologically active compounds: The present invention provides compositions and methods for the controlled release delivery of one or more biologically active compounds to a subject. Specifically, the invention provides for a pharmaceutical composition for the controlled release delivery of biologically active compounds to a subject comprising: a) a complex of a biologically active...

20060034925 - Tumor targeting drug-loaded particles: A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles...

20060034927 - Means of delivering drugs in an ascending zero order release pattern: Disclosed are dosage forms and methods for sustained release of a drug including: a delay layer comprising a polymeric matrix, and microencapsulated drug, wherein the delay layer is substantially free of non-microencapsulated drug; and a second layer including a polymeric matrix, and non-microencapsulated drug matrix; wherein the second layer is...

20060034928 - Tablet comprising cetirizine and pseudoephedrine: The present invention concerns a tablet comprising two distinct segments. More particularly, the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders....

20060034929 - Sustained release drug delivery devices with prefabricated permeable plugs: The present invention is directed to an improved sustained release drug delivery device comprising a drug core, a unitary cup, and a prefabricated permeable plug....

20060034930 - Apparatus and methods for sealing a vascular puncture: Apparatus for sealing a puncture communicating with a blood vessel includes a porous carrier formed from lyophilized hydrogel or other material. The plug may include at least first and second hydrogel precursors and a pH adjusting agent carried by the porous carrier in an unreactive state prior to exposure to...

20060034932 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions....

20060034931 - Solvent-assisted loading of therapeutic agents: Methods are provided for loading polymeric regions of medical devices with therapeutic agents. In these methods, a polymeric region of a medical device is first pretreated with a solvent system. Subsequently, therapeutic-agent-containing particles are impacted into the pretreated polymeric region at a velocity that is effective to at least partially...

20060034934 - Agglomeration of sterol particles: Disclosed are agglomerates of sterol particles comprising sterol particles having a mean particle size of equal to or less than about 100 microns. Also disclosed are methods for producing the agglomerates of sterol particles that include contacting sterol particles with a liquid, or a liquid and binder, and drying the...

20060034935 - Compositions and methods for treating excessive bleeding: The inventive material is a unique family of externally used wound sealants based upon a binding agent of reactive submicron silica particles that, when hydrated, agglomerate in the form of a supramolecular cross-linked network serving as the structural framework facilitating clot formation. A thrombolytic cascade accelerant can be provided, optionally...

20060034933 - Freeze-dried lecithin nanometer powder injection of ursolic acid and its preparation method: The invention discloses a freeze-dried nanometer powder injection of ursolic acid and a preparing method thereof. It major composes of active material of ursolic acid, complex vehicle of nanometer powder, excipient of freeze-drying. Compared to other popular preparations, its advantages are high target application of liver, concentrate on the affects,...

20060034936 - Sensate compositions and delivery systems therefor: The present invention includes compositions for imparting a controlled-release sensation to the oral receptor areas of a user. The oral, controlled-release compositions include a sensate and a hydrated or swollen food-grade polymer which forms a matrix with the sensate. Sensates may include warming, cooling and/or tingling agents. Also included are...

20060034937 - Solid carriers for improved delivery of active ingredients in pharmaceutical compositions: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat...

20060034938 - Combination preparation of a biological response modifier and an anticancer agent and uses thereof: The present invention provides anticancer biological response modifier combinations. In accordance with an aspect of the present invention, there is provided a combination comprising: (i) a composition comprising small molecular weight components of less than 3000 daltons, and having the following properties: is extracted from bile of animals; is capable...

20060034939 - Body cavity washer, device for washing body cavity and method of washing body cavity: Mulling contents of an intestine 12 and a gas-liquid mixture is promoted to increase a contact area between adventitious moisture and detained feces at an increasingly fast rate, thereby fluidizing the detained feces. The use of a liquid component and a gas component in combination enables development of an adventitious...

20060034940 - Drinking water container containing gemstones and crystals: A bottle of drinking water includes a transparent body having a top with a neck portion to provide an outlet and a bottom upon which the body rests. A plurality of gemstones are arranged in the water within the body. The gemstones may move within the water as the body...

20060034941 - Organ preconditioning, arrest, protection, preservation and recovery: The present invention relates to a method for reducing electrical disturbance of a cell's resting membrane potential comprising administering an effective amount of a composition comprising an effective amount of a local anaesthetic and of one or more of a potassium channel opener, adenosine receptor agonist, an anti-adrenergic, a calcium...

20060034942 - Molluscicide delivery system: A delivery system for controlling attack by molluscs, comprising a plant fibre substrate onto which has been loaded a metallic salt, such as by spraying with or immersing the substrate in an aqueous solution of the salt, the metallic ion of that salt being one which is toxic to molluscs,...

20060034943 - Process for treating a biological organism: A biological organism suffering from cancer can be treated by administering a cancer cell cycle arresting drug; optionally administering a microtubule stabilizing agent; and exposing the cell cycle arrested cells to mechanical vibrational energy. The method selectively induces apoptosis in cancer cells....

20060034944 - Compositions for improving breast health in women: Disclosed are compositions and corresponding methods for treating fibrocystic breast disease or other breast-related disease or condition. The compositions comprise, per serving or dose, from zero to about 400 μg selenium, from about 100 mg to about 6000 mg gamma linolenic acid, and about 0.15 mg to about 5 mg...

20060034945 - Composition for restoring damaged skin: The present invention provides a composition for repairing injured skin containing saccharide and povidone-iodine of the present invention having characteristices of suppressing time-dependent increase of consistency, easy to use, soft preparation, and superior applicability to a deep wounded lesion and a granulation tissue. The composition for repairing injured skin comprises...

20060034946 - Irrigating solution for neurosurgical procedures: During neurosurgical procedures, surgeons are still using physiological saline to irrigate. Saline is harmful during neurosurgical procedures. An irrigating solution to replace the use of saline is provided. The irrigating solution includes magnesium, colloidal osmotic agent, insulin and ATP in artificial CSF....

20060034947 - Erythritol compositions for nasopharynx cleansing: A cleansing composition for use in cleansing a subject's nasopharynx can include an effective amount of erythritol admixed with an acceptable carrier. The cleansing composition can be configured to be capable of being applied to the nasopharynx through the subject's nostril. Additionally, a method of cleansing a subject's nasopharynx can...

20060034948 - Method for treating an environment that may be or is contaminated with an undesirable bacterial, virus and or spore: The invention is directed to a method of decontaminating environments that are suspected of or known to be contaminated with undesirable biological agents, i.e., bacteria, viruses and/or spores, using nano-crystals that penetrate the cell wall of the undesirable agent to neutralize the agent. In one embodiment, the method comprises providing...

20060034950 - Herbal preparation for management of cardiovascular and neurologic disoders: A herbal preparation for management of cardiovascular and neurologic disorders comprising at least two of the following constituents, and preferably all three: 1. Dioscorea bulbifera, 2. Hippophae rhamnoides, 2. Bacopa monnieri and present in the range of: 1. Dioscorea bulbifera 200-500 mg, 2. Hippophae rhamnoides 150-400 mg, 3. Bacopa monnieri...

20060034949 - Remedy: The present invention relates to a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an insulin-mimetic action agent, a food, beverage, or feed for treating or preventing a disease accompanying an abnormality in an amount of insulin or insulin...

20060034951 - Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng: Provided is a composition that contains, as an active ingredient, an extract or polysaccharides separated from the leaves and/or stems of plants belonging to Panax genus, for an anticancer drug or its adjuvant, having an effect on the activity of hemotopoiesis enhancement, cancer metastasis inhibition, bone marrow defense, etc ....

20060034952 - Agent for inhibiting the growth of mammalian hair: The present invention comprises of a composition for post-hair-removal topical application for inhibiting mammalian hair growth & application thereof. The present invention also embraces a method of inhibiting mammalian hair growth by applying an effective amount of the composition to the skin. The composition comprises of a hair growth-inhibiting agent...

20060034953 - Ayurvedic nutritional preparation: The invention relates to an ayurvedic nutricinal preparation used as a prophylactic for cardiac ailments and for increasing cardiac muscle tonicity. The principal ingredient used are nuts from the plants belonging to the anacardiacieae family, Allium Sativum Linn and Zingiber Officinale Rosc. The toxins and irritants from the nuts are...

20060034954 - Medical composition for balancing bodily processes: Medical compositions and methods using same to nutritionally support balance of bodily processes are disclosed. A medical composition to nutritionally support balance of bodily processes involving S-adenosylmethionine is disclosed....

20060034955 - Pine cone extracts and uses thereof: A method of producing a pine cone extract and the pine cone extract produced there from, wherein the pine cone extract is useful in increasing the effects of nucleic acid vaccines and medicaments; and useful in the production of phenotypically immature and/or mature dendritic and/or fibrocyte cells....

20060034956 - Biologically active composition: A biologically active composition which has desirable properties, for example, anti-microbial and anti-cancer properties is disclosed. A process for preparing active ingredient(s) of the composition of the present invention, including, for example, extraction of the active ingredient(s) from a natural product is also disclosed. The biologically active composition may be...

20060034957 - Vitamin-containing system for stabilising the immune response of animals: A vitamin-containing system for stabilising the external and the internal immune response of animals consists of two parts or “kits” to be used successively or separately, one mainly including biotin and the other mainly including vitamins E and C. Both kits include allicin and crushed radishes and are mixed in...

20060029543 - Treatment of b-cell lymphoma: A method of treating B-cell lymphoma comprises administering to a patient a chemotherapeutic regimen, followed by treatment with a radiolabeled anti-CD20 antibody, wherein at the time of said treatment with said radiolabeled antibody said patient is not refractory to said chemotherapeutic regimen and has not relapsed....

20060029545 - Radiolabeled annexins: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided....

20060029544 - Receptor-binding cyclic peptides and methods of use: The present invention provides novel receptor-binding cyclic peptides that advantageously display high receptor binding affinity and selectively. More particularly, the present invention provides integrin-binding cyclic peptides containing an integrin-binding motif such as an RGD motif, an aromatic amino acid such as a tyrosine residue, and a lysine residue having a...

20060029547 - Biological materials and methods useful in the diagnosis and treatment of diseases: The present invention relates to a method of making a β-form of a prion protein which preferably has more β-sheet than α-helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use...

20060029546 - Materials and methods for identifying anti-schizophrenic agents: The invention relates to materials and methods of identifying modulators of N-methyl-D-Aspartate (NMDA) receptor phosphorylation and function, including anti-schizophrenic agents that modulate NMDA receptor function. The methods of the invention utilize animal models of schizophrenia and cell-based assays to identify modulators of NMDA function. The invention further provides anti-schizophrenic agents...

20060029549 - Measurement of protein synthesis rates in humans and experimental systems by use of isotopically labeled water: Provided herein are methods for measuring protein biosynthesis by using 2H2O or radioactive 3H2O and applicable uses thereof....

20060029548 - Methods of diagnosing, monitoring and treating pulmonary diseases: The invention includes methods of discriminating asthma from obstructive pulmonary disease, of treating pulmonary diseases, of treating cough, of assessing the efficacy of a treatment for an obstructive pulmonary disease, and of inhibiting activation of a P2-purinoreceptor (P2R)....

20060029550 - Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom...

20060029552 - Carrier particles for use in dry powder inhalers: A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material (4) on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the...

20060029551 - Stable particle formulations of erythropoietin receptor agonists: A particle formulation includes an erythropoietin receptor agonist, a buffer, and a sugar, wherein the buffer and sugar stabilize the erythropoietin receptor agonist against aggregation....

20060029553 - Deodorant spray preparations: A deodorant spray preparation containing (A) an antiperspirant and/or an antimicrobial agent, (B) an unsaturated fatty acid, (C) an antioxidant, and (D) a propellant. The deodorant spray preparation prevents the formation of white resides due to the sprayed powder, and provides a pleasant feeling upon use such as silky feeling....

20060029554 - Dual component dental composition containing enzyme: A two component desensitizing dentifrice composition is disclosed which comprises a first dentifrice component containing an enzyme such as papain and a second dentifrice component containing an ionic surfactant such as sodium lauryl sulfate, the first and second dentifrice components being maintained separate from the other until dispensed for application...

20060029556 - Aqueous-alcoholic depigmenting gels: Topically applicable, stable and non-irritating aqueous-alcoholic cosmetic/dermatological gels suited for cutaneous depigmentation contain water, at least one alcohol, at least one gelling agent, at least one phenolic compound, at least one retinoid, and, optionally, at least one sunscreen, formulated into a topically applicable, physiologically acceptable medium therefor....

20060029555 - Compositions and methods for prevention of photoaging: Methods of preventing photoaging and sun burn by topically applying a composition containing caffeine or a compound structurally similar to caffeine are provided. Pharmaceutical compositions comprising caffeine or a compound structurally similar to caffeine for the prevention of photoaging and sun burn are also provided....

20060029558 - Compositions and methods for controlling infections: The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds....

20060029557 - Natural hair care composition, methods for obtaining the same and use thereof: Disclosed is a natural hair care composition comprising extract of flowers of plant Butea frondosa and/or stem bark of plant Butea parviflora, and/or the exudates of stem and root of plant Butea superba, and a cosmetically acceptable carrier. Also disclosed are methods for obtaining the plant extract and use thereof...

20060029559 - Hair care composition: (1) The invention provides a composition for hair that imparts to the hair such properties as moist feeling, the feel of smoothness, thick-film touch, and ease of combing. These properties are long lasting and do not disappear after repeated brushing. Furthermore, neither in a moist state during washing, nor in...

20060029560 - Two-coat cosmetic product comprising at least one silicone polymer: The present disclosure relates to a cosmetic product comprising at least one first and at least one second compositions, wherein the at least one first composition comprises a silicone polymer of formula (I) and the at least one second composition comprises a cosmetically acceptable medium. The present disclosure also relates...

20060029562 - Personal cleansing composition containing a per-alk(en)yl hydrocarbon material: The compositions of the present invention relate to personal cleansing compositions that provide increased hair volume and superior styling benefits. These compositions comprise a surfactant system, a per-alk(en)yl hydrocarbon material having a molecular weight less than about 4200 and a particle size of from about 0.01μ and 40μ, a cationic...

20060029561 - Polysaccharide graft copolymers and their use in personal care applications: A graft copolymer comprises a polysaccharide polymer grafted with a polymer capable of bonding to human hair and is useful in hair care compositions....

20060029563 - Cutanceous metabolic bio-activator: The invention relates to a cosmetic composition comprising a bio-active system which combines (i) a stable form in aqueous solution of ATP (adenosine-tri-phosphate) with optionally an ATP precursor, e.g. Gp4G (diguanosine tetraphosphate), or Ap4A (diadenosine tetraphosphate), and (ii) at least one biomimetic peptide comprising at most six amino acids, mimicking...

20060029564 - Compositions for sustained release of volatile materials: Compositions comprising polytetramethylene glycol and a volatile material (e.g. a perfume) are able to sustainedly release said volatile material and are easy to disperse in liquid and cream products....

20060029566 - Self-heating non-aerosol shave product: Self-heating non-aerosol shave products are provided. In some implementations, the shave product includes a non-ionic emulsifier system, for example, including one or more fatty alcohol ethoxylates....

20060029565 - Self-heating shave foam product: Self-heating shave foams and shave foam products are provided. In some implementations, the shave foams include a non-ionic emulsifier system, for example, including one or more fatty alcohol ethoxylates....

20060029567 - Material for odor control: The present invention is directed to materials containing an enzyme inhibitor, including treated fibers, nonwovens, functional particles and processes for making these materials. These materials are useful in reducing or delaying onset of odor generation from various waste materials including human and animal elimination products....

20060029568 - Anionic polymers as toxin binders and antibacterial agents: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the...

20060029569 - Water-in-oil emulsions with anionic groups, compositions, and methods: Water-in-oil emulsions, compositions, and methods that include a vinyl polymer having a pKa of less than 4 that includes anionic group-containing side chains and alkyl-Y-containing side chains, wherein Y is O or NR, wherein R is hydrogen or methyl, and wherein the alkyl group of the alkyl-Y-containing side chain has...

20060029571 - Stabilized hyaluronan preparations and related methods: Stabilized hyaluronan preparations wherein hyaluronan is combined with a polyglycol, such as polyethylene glycol. Stabilized hyaluronan preparations of this invention may maintain their viscosity and lubricity for extended time periods (e.g., 2 years) without requiring refrigeration or special storage conditions....

20060029570 - Therapeutic peg solution concentrate: The present invention provides a polyethylene glycol liquid concentrate for treatment of constipation or for gastrointestinal lavage that is chemically stable and resistant to microbial contamination....

20060029572 - Treatment of hepatitis c in the asian population with subcutaneous interferonbeta: The present invention relates to the use of recombinant IFN-beta for the production of a medicament for the treatment of HCV infection by subcutaneous administration to patients of Asian race, which failed to respond to a previous treatment with interferon-alpha, is herein reported. According to a preferred embodiment of the...

20060029573 - Pegylated interferon alpha-1b: The invention provides PEG-IFN α-1b conjugates, where a PEG moiety is covalently bound to Cys86 of human IFN α-1b conjugates. A pharmaceutical composition and a method for treating inflammatory diseases, infections, and cancer are also provided. The invention further relates to a method for the modification of interferons by conjugation...

20060029574 - Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity: The present invention provides methods and compositions for identifying cancer cells that are either sensitive or resistant to a particular anti-cancer therapy. Accordingly, the present invention allows for more accurate diagnosis, prognosis, and monitoring of a subject's condition. Furthermore, the ability to assess a subject's resistance or sensitivity to a...

20060029575 - Compositions and methods for producing and using homogenous neuronal cell transplants: Methods of treating individuals suspected of suffering from diseases, conditions or disorders of the Central Nervous System which comprise implanting stable, homogeneous post-mitotic human neurons into the individual's brain are disclosed. Methods of treating individuals suspected of suffering from injuries, diseases, conditions or disorders characterized by nerve damage which comprise...

20060029583 - Method for the genetic activation of cells and uses of said cells: Mammalian cells, normally dependent of IL-2, can be successfully transfected to express IL-2 in amounts sufficient to sustain growth without the external addition of IL-2. One cell line expressing IL-2 solely in the endoplasmatic reticulum without secretion, and one cell line capable of secretion of IL-2 have been developed and...

20060029584 - Methods for improving cell line activity in immunoisolation devices: Methods for maintaining and improving the secretory activity of cells housed in immunoisolation devices....

20060029582 - Methods of treating neoplasia with combinations of target cell-specific adenovirus and chemotherapy: The invention provides methods of treating neoplasia using combinations of target cell-specific replication competent adenoviral vectors and chemotherapy, radiation therapy or combinations thereof. The adenoviral vectors are target cell-specific for the particular type of neoplasia for which treatment is necessary and the combination with the chemotherapy and/or radiation leads to...

20060029576 - Biological control of pythium disease in crops: Strains of Rhizobium leguminosarum biovar viceae have antifungal activity against the pathogen Pythium ultimum. Compositions and methods for treating or protecting plants susceptible to Pythium ultimum damage, and Pythium sp. “group G” damage in particular, are provided. Such strains include, for example, the strains deposited in the International Depository Authority...

20060029577 - Method for drying biomaterials: The present invention provides a means to concentrate, dry and formulate biomaterials such as polysaccharides, gums and related biopolymers, and microorganisms such as cells, spores, and the like from dilute solutions using spent germ and other oil bearing residues. In addition, the spent germ can serve as a carrier for...

20060029585 - Methods for reducing morbidity: Various compositions containing transfer factor in combination with nutraceuticals are provided including transfer factor in combination with zinc and essential fatty acids and transfer factor in combination with lactic acid generating bacteria. Also provided are methods for treating animal diseases and syndromes using these compositions....

20060029578 - Composition and method for the repair and regeneration of cartilage and other tissues: The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere...

20060029581 - Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells: The invention relates to the field of hematopoietic CD34+ cell mobilization. In particular, this invention relates to a method for increasing the mobilization of pluripotent hematopoietic CD34+ cells by administration of human growth hormone or one of its derivates to the individual....

20060029580 - Method for treating a condition with neural progenitor cells derived from whole bone marrow: A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to...

20060029579 - Methods and compositions for producing target cell reactive lymphocytes in a subject: Methods and compositions for producing target cell reactive lymphocytes, e.g., cytolytic T-lymphocytes, in a subject are provided. In practicing the subject methods, a lymphocyte population is contacted with an effective amount of a target cell peptide mixture of active and inactive peptides to produce lymphocytes reactive, e.g., cytolytic, for the...

20060029587 - Peri-operative and peri-procedure nutritional supplementation: The invention provides a nutritional supplement system and program for patients undergoing or who have undergone a surgical or other invasive or stressful procedure, or who have suffered an injury. This nutritional supplement for the peri-operative period is designed to prevent deficiencies of nutrients needed for optimal health and healing...

20060029586 - Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates: in which A is an active agent comprising an active hydroxy or amino functionality and B is a biopolymer comprising an active hydroxy or amino functionality, and X1 and X2 are independently N or O, and R is substituted alkyl or unsubstituted alkyl or unsubstituted or substituted heteroalkyl from 1...

20060029588 - Lysyl oxidase-like 1 (loxl1) and elastogenesis: Described are methods of treating and preventing conditions associated with a loss of elastic fibers. Also provided herein are methods of screening for agents useful in treating such conditions, and animal models of conditions associated with a loss of elastic fibers....

20060029590 - Administration of neutral endopeptidase to treat inflammatory bowel disease: Administration of recombinant, truncated mammalian NEP or certain bacterial homologues of this protein is therapeutically effective in the treatment of inflammatory bowel disease....

20060029589 - Induction of heterozygous fv leiden carrier status to reduce mortality in sepsis and to prevent organ damage caused by inflammation and/or ischemia-reperfusion injury: A method of treating a disease is disclosed. In one embodiment, the method comprises administering to a patient an effective amount of factor V protein or fragment of factor V protein, wherein the amount of protein is sufficient to alleviate or prevent disease symptoms and wherein the protein is resistant...

20060029591 - Repair of larynx, trachea, and other fibrocartilaginous tissues: Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues...

20060029592 - Methods of treating peripheral arterial occlusions: A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of α2-macroglobulin in the circulating blood. A method is also provided for...

20060029593 - Humanised antibodies: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise...

20060029595 - Methods of using human receptor protein 4-1bb: Disclosed herein are the methods of using the H4-1BB protein, ligands to this protein, and various mAbs either directed against H4-1BB or other molecules that can be used therapeutically. The nature and importance of the H4-1BB molecule provides the ligands and related co-stimulatory molecules the ability to enhance or suppress...

20060029594 - Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided....

20060029596 - Replication-competent anti-cancer vectors: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are...

20060029597 - Iga antibody protein as a cytotoxic drug: Novel compounds are disclosed. The compounds are useful for inducing apoptosis, cell death and/or inhibiting proliferation of cells. Also disclosed are pharmaceutical compositions and methods associated with the compounds....

20060029598 - Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient....

20060029599 - Stable lyophilized pharmaceutical formulation of igg antibodies: This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e.g. 50 mg/ml or more, of an IgG antibody in about 5-25 mM histidine buffer having pH from about 5.5 to about 6.5, about 0.005%-0.03% polysorbate, sucrose, and optionally serine,...

20060029600 - Treatment of viral encephalitis by agents blocking alpha-vla-4 integrin function: The invention provides methods of treating viral encephalitis in a patient. Such methods entail administering to the patient an effect amount of an agent that inhibits binding of leukocytes to brain endothelial cells via leukocyte surface antigen alpha-4 integrin. Such agents include antibodies and small molecules that specially bind to...

20060029602 - Gamma-heregulin: A novel member of the heregulin superfamily has been identified which is designated “γ-HRG”. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner. γ-HRG polypeptide and nucleic acid are...

20060029603 - Immunoglobulins: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders....

20060029604 - Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform: The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is GlcNAc2Man3GlcNAc2....

20060029601 - Interferon alpha receptor 1 antibodies and their uses: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated...

20060029605 - Use of erbb receptor ligands in treating diabetes: The invention provides methods for treating pancreatic dysfunction, particularly diabetes, in mammals using ErbB receptor ligands, such as heregulin, betacellulin, and EGF. Methods of treating such conditions using anti-ErbB receptor agonist antibodies are further provided. The methods of the invention may be performed by direct administration of such therapeutically useful...

20060029606 - Method for use of igf-binding protein for selective sensitization of target cells in vivo: New methods for the treatment of human disease are provided. IGFBP-3 is administered together with a co-administered agent to subjects having disease, thereby alleviating the symptoms of the disease, under conditions where administration of IGFBP-3 alone at the maximum practicable dose has no measurable beneficial effect on the disease condition....

20060029607 - Methods and compositions for modulating tumor growth: Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing...

20060029608 - Immunization against clostridium difficile disease: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of...

20060029609 - Use of the chaperone receptor-associated protein (rap) for the delivery of therapeutic compounds to the brain and other tissues: This invention provides compounds of conjugates of therapeutic or active agents with RAP or a RAP polypeptide, their pharmaceutical compositions and methods for using the such compounds and compositions in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly diseases of the central nervous system or lysosomal storage...

20060029610 - Grp94-based compositions and methods of use thereof: Mini chaperones and methods of use thereof for the treatment of cancer and other disorders are provided. Also provided are tools to facilitate screening therapeutic agents which have selective binding affinity for GRP94....

20060029611 - Prevention and treatment of amyloidogenic disease: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is...

20060029612 - Prevention and treatment of recurrent respiratory papillomatosis: Juvenile-onset recurrent respiratory papillomatosis is treated using active vaccination or passive immune therapy of neutralizing antibodies against HPV L2 neutralizing epitopes....

20060029613 - Biological compositions and methods for treatment of cervical cancer: The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with cervical cancer. The biological compositions can be used to retard the growth of cervical cancer cells and/or prolonging the time of survival of the subject. The...

20060029614 - Methods and compositions for treating gastroparesis: Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to treat gastroparesis in a subject (e.g., stimulating stomach contraction, reducing abnormal gastric acid and/or pepsin production), as a result of having been cultured in the presence of an alternating electric field...

20060029615 - Novel recombinant t4 phage particle and uses thereof: The invention is directed to a novel recombinant T4 phage particle expressing a HOC and/or SOC fusion peptide as well as methods for their preparation and methods of use in compositions and kits....

20060029616 - Plasmid maintenance system for antigen delivery: The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two independent levels by: (1) removing sole dependence on balanced lethal maintenance...

20060029617 - Porcine circovirus and helicobacter combination vaccines and methods of use: The present invention is based on the discovery of novel species of the genus Helicobacter that are associated with gastro-esophageal ulceration in pigs. In particular, a novel species, H. cerdo, has been used as a source of antigenic material for the development of vaccine for the treatment of the gastro-esophageal...

20060029618 - Vaccine against dental caries based on virulence-associated immunomodulatory extracellular proteins produced by the cariogenic bacteria streptococcus sobrinus and streptococcus mutans: This invention is concerned with a vaccine against dental caries obtained from the supernatant over cultures of the cariogenic bacteria Streptococcus sobrinus and S. mutans that consists of extracellular proteins. These proteins provide the suppression of the immune response in the host through the early production of IL-10, an anti-inflammatory...

20060029619 - Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter: The invention concerns recombinant Modified vaccinia virus Ankara comprising in the viral genome an expression cassette comprising the cowpox ATI promoter or a derivative thereof and a coding sequence, wherein the expression of the coding sequence is regulated by said promoter. The virus may be useful as a vaccine or...

20060029620 - Mycobacterium smegmatis vaccine: The present invention is about a mycobacterium smegmatis vaccine, a split product of mycobacterium smegmatis. This vaccine has made good use of the adjuvant function of bacterial cellwall and antigenic specificity of tropina which can stimulate the production of cytokine and consists of many immunologically competent CpG fragments of bacteria...

20060029621 - Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis: The present invention generally provides methods and vaccines for the prevention of diseases caused by Neisseria meningitidis bacteria, particularly serogroup B strains....

20060029623 - Invert emulsions comprising at least one active agent sensitive to water and cosmetic/dermatological applications thereof: Cosmetic/dermatological compositions useful for the treatment of a variety of dermatological conditions, including keratinization disorders, acne, eczema, psoriasis, etc., comprise an invert emulsion containing at least one active agent sensitive to the presence of water, notably a derivative of vitamin D, and solubilized in a glycolic or hydroglycolic dispersed hydrophilic...

20060029622 - Water in oil emulsion comprising sterolesters: The invention relates to water in oil emulsions comprising a sterol fatty acid ester to which folic acid has been added to counter act the effect of the sterol fatty acid ester on the droplet size of the dispersed aqueous phase....

20060029627 - Antipruritic composition and wound-healing-promoting composition: An antipruritic composition and a wound-healing-promoting composition which comprise Sasa albo-marginata (13ambooseae Sasa) extract in an amount ranging from 1 to 10% by mass as expressed in terms of the solid content thereof. The composition of the present invention comprises the Sasa albo-marginata extract in a concentration substantially higher than...

20060029626 - Cosmetic composition: wherein R1 and R2 each independently represents a straight or branched-chain alkyl group having 1 to 21 carbon atoms or a straight or branched-chain alkenyl group having 2 to 21 carbon atoms. The cosmetic composition imparts much moistness and superior conditioning effects such as body or elasticity to hair, and...

20060029624 - Low-residue deodorant or antiperspirant stick based on an oil-in-water dispersion: Deodorant or antiperspirant sticks based on an oil-in-water dispersion for application to the skin....

20060029625 - Personal cleansing composition containing fibers: Personal cleansing compositions comprise (a) from about 5 wt. % to about 50 wt. % of a water-soluble detersive surfactant; (b) at least about 0.1 wt. % of a fiber having a length and a thickness such that said length is greater than said thickness, wherein said length is from...

20060029629 - Absorbent garment with incorporated skin wellness ingredients: An absorbent garment comprising skin wellness ingredients is disclosed, where the skin wellness ingredients are incorporated into an adhesive used in the assembly of the garment. By incorporating the skin wellness ingredients into the adhesive, the skin wellness ingredients can be precisely placed on those portions of the absorbent garment...

20060029628 - Use of a volatile cooling sensate on fibrous tissues to provide a sensation of rhinological decongestion: A tissue useful in providing fibrous tissue products for skin contact, such as facial tissue, bathroom tissue, toilet tissue, disposable handkerchiefs comprising a volatile cooling sensate effective on human skin by causing a cold feeling to provide sensation of rhinological decongestion without directly causing a change in skin temperature....

20060029630 - A method for admixing plant essential oils to coatings (paints, stains, etc) for the purpose of repelling insects during coating application and introducing an insect repellant nature to the cured or dried film: The Federal EPA has consistently limited the use of known toxicants (insecticides) to preclude their admixture into paints and coatings by contractors or homeowners for the purpose of repelling or killing insects on the dried or cured coating. The current invention utilizes materials taken from the EPA's GRAS (Generally Recognized...

20060029631 - A method for admixing plant essential oils to coatings (paints, stains, etc) for the purpose of repelling insects during coating application and introducing an insect repellant nature to the cured or dried film: A process for eradicating moss and liverwort which includes applying sodium percarbonate; and irrigating the moss. In some cases the process includes applying lime to control the pH of the moss and thereby constrain development of additional moss and said sodium percarbonate is a solid material....

20060029632 - Insecticides and arachnicides: A non-toxic insecticide or arachnicide comprises insecticide or arachnicide in finely divided form comprising: a) insecticidal or arachnicidal cellulosic material obtainable from the core of corncobs, and b) optionally an attractant, said cellulosic material interfering with the digestion of insects or arachnids and said insecticide or arachnicide being non-toxic to...

20060029633 - Biological patch for use in medical procedures: A method for forming a patch using a laminated material and a process for forming the laminated material. Also a plurality of patches using the laminated material for various implantation purposes into an anatomy. In addition, an implant method for implanting one or a plurality of the selected patches for...

20060029635 - Growth hormone formulations: A multi-dosage, storage stable liquid human growth hormone formulation consisting essentially of growth hormone in isotonic phosphate buffered solution, a preservative and a non-ionic surfactant, wherein isotonicity of the phosphate buffered solution is provided by a compound selected from the group consisting of a neutral salt, a monosaccharide, a disaccharide,...

20060029634 - Porous structures: A polyelectrolyte multilayer can be deposited on a surface and converted to a porous structure by aqueous processing. The porous structure can be loaded with a compound....

20060029636 - Medical devices and methods for reducing localized fibrosis: Medical devices and methods for reducing localized fibrosis at the site of the medical device....

20060029637 - Methods for manufacturing delivery devices and devices thereof: Described herein are methods for reducing and achieving the desired release of an agent from a delivery system. The desired release kinetics are achieved by exposing the surface of the delivery system with a fluid for a desired period of time....

20060029638 - Methods for treating body tissue: Methods of treating body tissue including repairing defects in body tissue as well as augmenting body tissue. Body tissue defects are repaired by injecting a polymeric adhesive composition through an injector into the region of the defect and allowing the adhesive composition to cure to repair the defect or to...

20060029639 - Biodegradable substrate, prosthetic material for tissue regeneration, and cultured tissue: A biodegradable substrate usable as a prosthetic material (i.e., for tissue regeneration) facilitates the invasion of cells into a substrate and has a thick structure similar to woven fabrics. The biodegradable substrate is obtained by stitching a biodegradable nonwoven fabric with a biodegradable thread. An embodiment of the nonwoven fabric...

20060029640 - Medical devices with surface modification for regulating cell growth on or near the surface: High oxidation state metal-containing compounds are formed on or applied to the surfaces of medical devices. These compounds can cause cytostatic, cytotoxic, and anti-proliferative effects to the cells on or near the implanted medical devices and thus reduce or eliminate undesirable cell growth or accumulation on the medical devices....

20060029641 - Calcium and magnesium nutritional supplement: The present invention provides a method and composition for dietary mineral supplementation utilizing a form and dosage of calcium and magnesium for enhanced calcium absorption. The method includes the steps of delaying the absorption of the magnesium for a period of time after absorption of the calcium component of the...

20060029643 - Food for skin moisture retention: This invention relates to a food containing a glycosylated ceramide and diacylglycerol. This food is capable of improving and enhancing the barrier function of skin and increasing water holding capacity of the skin....

20060029642 - Methods and compositions for improved chromium complexes: Complex metal-containing matrices, and especially chromium-containing matrices are produced from a water soluble preparation that is derived from an item suitable for animal (and most typically human) consumption. In particularly contemplated aspects, the water soluble preparation is an extract or filtrate of disintegrated brewer's yeast, and the so prepared complex...

20060029644 - In vitro biochemical reactions with free anhydrous d-ribose: This invention discloses the spontaneous endothermic chemical reaction at room temperature that anhydrous D-ribose undergoes with one or more molecules, forming new molecules involving the ribose radical and also those reactions that require elevated temperatures for a rapid reaction, including amino acids that form protein and polypeptides, as well as...

20060029645 - Acid-containing feed supplements for ruminants and methods of manufacturing same: This application relates a flowable feed supplement for ruminant animals such as cattle comprising a liquid acid adsorbed on a granular inorganic substrate. The inorganic substrate may be combined with an organic carrier such as source of slowly fermentable carbohydrates. In one embodiment the inorganic substrate is silicon dioxide. The...

20060029646 - Anionic-containing feed supplements having a low protein by-pass value: The present invention provides anionic-containing feed supplements having a low protein by-pass value that may be administered to animals. In particular, the invention provides anionic-containing feed supplements that are granular and may be utilized to treat several metabolic disorders in animals, such as hypocalcemia, milk fever, and ketosis....

20060029647 - Composition and method for use in cartilage affecting conditions: A method for managing cartilage affecting conditions, increasing cartilage flexibility, increasing cartilage strength, or preventing cartilage degradation in an animal using glycine, proline, or a combination of glycine and proline....

20060029650 - Combination sis and vacuum bandage and method: A wound care bandage for treating a wound is provided. The bandage includes an SIS layer to be placed on the wound surface and a cover to placed over the wound. The bandage further includes a structure to provide a vacuum space. A method for promoting wound healing is further...

20060029649 - Stabilized antimicrobial agents: The present invention provides antimicrobial compositions comprising an antimicrobial agent and a thermally stabilizing effective amount of an amide based stabilizing agent. The present invention also provides polymeric-cellulosic fiber formulations comprising a polymeric-cellulosic fiber composition and an antimicrobially effective amount of the antimicrobial composition. The present invention further provides a...

20060029648 - Stimulant/desensitizer swabs: A method and pharmaceutical composition for treating the sexual dysfunction of premature ejaculation is disclosed. The pharmaceutical composition consists of a solution of one or more stimulants and a desensitizer. The stimulant is selected from the group comprising spearmint solution, peppermint solution, cool mint solution, pepper solution, alcohol, rubbing alcohol,...

20060029651 - Dressing and method of treatment for a wound: A dressing and method for treating high-tension wounds. First and second layers of a 2-octyl cyanoacrylate 16 adhesive are applied to a short, high-tension wound, with the first and second layers covering the wound and extending to at least about 2.5 mm (0.0984 in.) from each side of the wound....

20060029652 - Absorbent hydrogel compositions: The invention provides an absorbent (porous) hydrogel composition comprising a foam portion which comprises a flexible plasticised hydrophilic polymer matrix having an internal cellular structure, and a continuous portion which comprises a flexible plasticised hydrophilic polymer matrix having a relatively continuous internal structure. The continuous portion of the hydrogel composition...

20060029653 - Therapeutic delivery system: Therapeutic delivery systems are provided which, in a first embodiment, contain a plurality of multiphase capsules in which first and second therapeutic agents are contained in separate phases within said multiphase capsules, and are disposed to deliver said first and therapeutic agents by at least two different delivery mechanisms....

20060029654 - Analgesic patch for sports injury rehabilitation medicine and method to alleviate pain: The present invention relates to a method for topical treatment of pain resulting from a sports injury, including injuries to bones and soft tissue, such as ligaments, muscles or tendons. The method includes the steps of: applying to skin of a subject suffering from pain resulting from a sports injury...

20060029655 - Method for preparation of vesicles loaded with biological material and different uses thereof: The present invention discloses a method for an efficient entrapment of active biological material in liposomes. The method is based on the steps of drying a suspension of liposome-forming lipids and then hydrating the dry composition obtained with an aqueous solution containing a biologically active material to be entrapped in...

20060029656 - Replacement enzyme cochleates: Disclosed are cochleates and cochleate compositions that associated with an replacement enzyme component and/or a plasmid component that encodes a replacement enzyme. Also disclosed are methods of making and using the compositions of the invention, including methods of administration. Use of the invention provides safe, effective and efficient delivery of...

20060029658 - Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs: The invention provides a formulation of one or more antineoplastic drugs encapsulated in liposomes including at least a lipid fraction in addition to the antineoplastic drug, wherein the composition is stable in an aqueous solution at room temperature....

20060029657 - Topical skin protectant compositions: Skin protectant compositions that are free of cholesterol and suitable for topical application to skin of a mammal. In a preferred embodiment, these skin protectant compositions comprise a ceramide; a squalane; a phytosterol-containing liposome; a phospholipid-containing ingredient; at least one triglyceride; and at least one dermatologically acceptable excipient. These compositions...

20060029659 - Immune dengue plus: An immune enhancing blood platelet builder that increases the survival rate of the patient against the duration of the dengue fever virus in the body....

20060029660 - Non-gelatin capsule shell formulation: A film-forming hydrocolloid composition comprising kappa carrageenan, iota carrageenan, a bulking agent, plasticizer and water is described. The ratio of bulking agent to total carrageenan is from about 1:1 to 20:1. Kappa carrageenan is present in an amount of less than or equal to 50% by weight of total carrageenan...

20060029661 - Orally administrable pharmaceutical formulation: The present invention relates to pharmaceutical formulations for oral administration through a soft gelatin capsule, wherein the pharmaceutical dosage form has pseudoephedrine hydrochloride as the active pharmaceutical ingredient. The active pharmaceutical ingredient, pseudoephedrine hydrochloride as an active is embedded in a suitable matrix, wherein said matrix composition is characterized by...

20060029662 - Immunomodulatory compositions and methods of use thereof: The invention relates to immunomodulatory compositions and related methods. The immunomodulatory compositions of a formula disclosed herein are useful for the prevention of sepsis and the treatment and prevention of diseases associated with inflammation and/or NOS....

20060029664 - Dosage form containing carbetapentane and another drug: A pharmaceutical dosage form which comprises carbetapentane and/or a pharmaceutically acceptable salt thereof and an additional drug. The dosage form provides a plasma concentration within the therapeutic range of the additional drug over a period which is coextensive with at least about 70% of the period over which the dosage...

20060029666 - Particle embedded with chemical substances and method of producing a particle: A particle embedded with chemical substances, especially with physiological activity substances, is disclosed. The particle has (a) the embedded substances, embedded in base materials and ranged from about 0.1 to 70% by weight based on the total weight of the particle; and (b) the base material, selected from hydrogenated plant...

20060029665 - Pilocarpine compositions and methods of use thereof: The present invention provides novel compositions for the delivery of pilocarpine or a pharmaceutically acceptable salt thereof across the oral mucosa, preferably across the buccal mucosa. In particular, the buffer systems in the compositions of the present invention contain an amount of a strong base that is less than the...

20060029663 - Solid formulation: e

20060029667 - Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents: The invention is directed to pharmaceutical compositions and methods for delivery of a therapeutic or diagnostic agent from one bodily compartment to one or more other bodily compartment by administering one of the following conjugates: a polymer having multiple functional groups at least one of which is covalently bound to...

20060029669 - Antidiabetic preparation for oral administration: There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing...

20060029668 - Sustained release l-arginine formulations and methods of manufacture and use: The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in part, on the discovery that administering to a subject a formulation comprising an agonist of endothelial nitric oxide synthase (eNOS), such as an...

20060029670 - Pharmaceutical formulations and method for making: The invention relates to a process of making an oral pharmaceutical formulation with variably adjustable release rate, which comprises one or more active ingredients, and one or more sucrose ester of a fatty acid as the sole release-controlling agent for said active ingredient wherein when the dosage form is a...

20060029671 - Tablet coating composition: Disclosed is a method for coating a tablet with a coating composition. The tablet generally comprises a biologically active material, and generally one or more biologically acceptable excipients. The coating composition comprises hemicellulose, partially depolymerized hemicellulose, or a mixture thereof. In preferred embodiments, the coating composition includes a plasticizer, and...

20060029672 - Silicone gel composition and dispenser therefor: A therapeutic silicone composition and a delivery device operable for the self-administration of the therapeutic silicone composition to the skin. Silicone gel compositions are known in the art to promote wound healing and reduce scarring. The therapeutic silicone composition of the present invention contains a silicone gel formulated with inert...

20060029675 - Method for coating substrate with antimicrobial agent and product formed thereby: A method for uniformly coating a foam or dressing with antimicrobial polymer incorporating agents, such as silver, and a foam or dressing formed by this process. Such foam or dressing is particularly useful in combination with negative pressure wound therapy....

20060029674 - Stable amorphous cefdinir: The present invention relates to stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer), methods for its preparation, and pharmaceutical compositions comprising stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer)....

20060029673 - Transdermal administration of (r)-3,3-diphenylpropylamin-monoesters: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3 alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium,...

20060029676 - Aqueous suspension of nanoscale drug particles from supercritical fluid processing: The present invention is directed to an improved supercritical fluid processing technique that can be used to form particulate suspensions of biologically useful materials. The disclosed processes include variations of RESS processes. The disclosed processes do not form micelles of any stabilizing agents in the aqueous solution that receives the...

20060029677 - Azithromycin dosage forms with reduced side effects: The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes...

20060029678 - Process for the production of implants: There is provided a process for the preparation of an implantable or injectable pharmaceutical composition suitable for the extended release of an active ingredient, such as a peptide or a peptide analogue, to a patient following administration, by a process that includes: (a) wet granulation of a mixture of active...

20060029679 - Autologous platelet gel having beneficial geometric shapes and methods of making the same: The present invention relates to the production of platelet gels formed into beneficial geometric shapes. Specifically the present invention provides a simpler way to introduce platelet gel for specific uses, such as into the cavity of a gum left after a tooth extraction. Molds of predetermined shapes are provided for...

20060029680 - Methods of preparing highly concentrated aqueous bromine solutions: The present invention is directed to convenient methods of preparing: (1) highly concentrated liquid bromine-containing biocidal solutions and (2) highly concentrated mixed halogen liquid bromine and chlorine-containing biocidal solutions that have excellent physical and chemical stability. One method involves adding the acidic reaction medium to an alkaline source to effect...

20060029681 - Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations....

20060029682 - Treatment of wounds and compositions employed: A synthesized composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when applied to an open wound, effectively modulates the activity of at least MMP-2 and/or MMP-9 in the wound. A method for treatment of wounds is disclosed....

20060029683 - Appendix of 2.7% ~ 9% saline, 56% saline: The name of invention is Saline and the Saline is NaCl sol. is distinguished by density. In this invention solution, Pus at wound can be removed without curettage and antibiotics by lysis of phosphatide of H+. In 2.7%˜9% Saline sol. of in potential power of semipermeable memb., Membrane formation and...

20060029684 - Synergistic treatment of dna viral infections: The synergistic combination of a loop diuretic and lithium is useful in the treatment of DNA viral infections....

20060029685 - Combination of unsaponifiable lipids combined with polyphenols and/or catechins for the protection, treatment and repair of cartilage in joints of humans and animals: The present invention relates to a composition and a kit for the protection, treatment and repair of cartilage in humans and animal joints. The composition or kit contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. Preferably, the composition or kit contains avocado:soybean unsaponifiables...

20060029686 - Cytokine modulators and related methods of use: A composition for modulating cytokines to regulate an inflammatory or immunomodulatory response. The composition can include at least one of rosehips, blueberry, blackberry, elderberry, cranberry, rosemary, clove, feverfew, nettle root, artichoke, reishi mushroom, olive extract, green tea extract, grape seed extract, resveratrol, Aframomum melegueta, boswellia serrata extract, boswellia forte, ipriflavone,...

20060029687 - Stabilized ascorbic acid solutions; use thereof; process for their obtention; and formulations comprising the same: This invention relates to improved solutions comprising ascorbic acid (vitamin C). These solutions may comprise as much as 15% ascorbic acid; they are stable for at least two years, without no significant development of yellowish coloration and no substantial (not more than 10%) degradation of the vitamin. The process involves...

20060029688 - Antiseptic composition: p-Menthane-3,8-diol (PMD) has antiseptic, antibiotic, fungicidal and bactericidal properties. It is used for these purposes in the form of compositions and method comprising the PMD and optionally a carrier. A method of treating acne, folliculitis body, scalp folliculitis, Hydradinitis suppuritiva dandruff, seborrhoeic dermatitis (scalp or body), pityriasis versicolor, pityrosporun folliculitis,...

20060029689 - Skin protection composition: The present invention provides: a skin protection composition that can effectively suppress intrusion of contagious bacteria such as Pseudomonas aeruginosa, Bacillus subtilis, Bacillus anthracis, Escherichia coli, Staphylococcus aureus, or MRSA, and viruses such as influenza virus from wounds, skin and mucosa such as those of the eyes, nose, throat, ears,...

20060029690 - Buckwheat compound and method of obtaining the same for treatment of hyperglycemia: A process for obtaining a compound from buckwheat and its use as a pharmaceutical treatment are disclosed. Methods of treatment using extracts of buckwheat are also disclosed....

20060024229 - Method and product for locating an internal bleeding site: A method is provided for localizing an internal bleeding site whereby a protein or other factor involved in the clotting process is complexed to an imaging agent and injected into a patient believed to be at risk of internal bleeding. A clot in the patient will naturally accumulate a certain...

20060024230 - Customized therapeutics and in situ diagnostics: Customized therapeutics and in situ diagnostics for patient therapy and diagnosis takes advantage of tools including techniques for derivatizing colloids with self-assembled monolayers. This provides the capability of a wide variety of assays including chemical or biochemical agent/agent interaction studies. Bio-derivatized colloids, with or without signaling entities, are used to...

20060024232 - Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface: Methods of delivering an agent in a tissue-specific manner, by targeting proteins expressed on endothelial cell surface, are described. The methods can be used for detecting, imaging and/or treating neoplasia, angiogenesis or neovasculature, as well as for diagnostics and methods of assessing treatment efficacy....

20060024231 - Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface: Methods of delivering an agent in a tissue-specific manner, particularly lung tissue, by targeting a protein expressed on the endothelial cell surface, are described. The methods can be used for detecting, imaging and/or treating pathologies, as well as for diagnostics....

20060024233 - Use of biomolecular targets in the treatment and visualization of brain tumors: The present invention relates to the use of proteins that are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents, which specifically bind to one...

20060024234 - Protein markers for pharmaceuticals and related toxicity: Protein markers of toxicity and efficacy for antilipemic drugs are determined. Methods and reagents are disclosed for determining whether a patient receiving an antilipemic drug, especially a statin or HMGCoA reductase inhibiting drug, is experiencing drug efficacy and/or toxicity. Individual susceptibility is also determined prior to treatment. Also, drug discovery...

20060024235 - Stabilised superparamagnetic particles: The invention relates to stabilized superparamagnetic particles which consist of superparamagnetic single domain particles and aggregations of superparamagnetic particles which are stabilized with aliphatic dicarboxylic or polycarboxylic acids and which contain charged ions of chemical elements on the surface of the small superparamagnetic single-domain particles and, optionally, an additional tissue...

20060024236 - Bowel preparation for virtual colonoscopy: The instant invention combines three distinct components to form a single effective bowel preparation for virtual colonoscopy (VC) examination: 4) a cathartic for colonic cleansing; 5) barium sulfate for stool tagging; and 6) water soluble iodinated contrast for colonic fluid opacification. Each component has been employed previously for VC preparation...

20060024238 - Compositions and methods using proton pump inhibitors: The invention provides methods for treating and preventing gastrointestinal disorders, viral infections, fungal infections, Whipple's disease, sleep disorders, sleep apnea, iron deficiency anemia, asthma, nasal airway resistance, cystic fibrosis, pancreatitis, chemotherapy-induced emesis, radiation-induced injury to the gastrointestinal tract, epilepsy, middle ear infections, obesity, hiatal hernia, anorexia, bulimia, dental decay, post-operative...

20060024237 - Dri nasal sprays: There are provided safe, tasteless, odorless, non-aqueous liquid spray compositions formulated for administration to the nasal cavity consisting essentially of pharmacologically acceptable non aqueous liquid carrier in which said bioactive material is directly insoluble, a pharmacologically acceptable water insoluble ester of a water soluble acid soluble in said carrier, a...

20060024239 - Persistent post-viral cough drug and treatment method: A drug for treating persistent cough occurring after an acute viral upper respiratory infection that has a corticosteroid aerosol for inhalation, and labeling to indicate short-term use of the agent for persistent post-viral cough. Also a method for treating persistent post-viral cough that utilizes such a drug....

20060024240 - Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are...

20060024242 - Solubilizing liquid of refractory element and producing method thereof: A method for solubilizing in water a refractory element not soluble in water can be a method of adding a refractory element to material water obtained by solving a solubilizer, and finely grinding the refractory element using a homogenizer. However, the mechanical method of grinding using a homogenizer cannot evenly...

20060024241 - Vitamin b12 compositions: The present invention provides improved vitamin B12 compositions containing a mixture of vitamin B12 analogues that are better absorbed into the bloodstream of a patient with vitamin B12 deficiency, preferably via their mucosal membranes and also discusses convenient and inexpensive delivery methods for these compositions without the discomfort of subcutaneous...

20060024243 - Foamable compositions containing nitro-imidazoles, processes for preparing same and methods of treatment utilizing same: A pharmaceutical or cosmeceutical foamable composition for topical application of nitroimidazoles such as Metronidazole and a process of manufacturing the same is disclosed. A method of treatment of skin and scalp disorders, especially of rosacea, acne and foul smelling lesions, by dispensing nitroimidazoles such as Metronidazole in foamable composition is...

20060024248 - Composition and method employing membrane structured solid nanoparticles for enhanced delivery of oral care actives: An oral care composition containing membrane-structured solid nanoparticles formed from a lyotropic liquid-crystalline mixed phase having an average particle diameter in the range of 10 to 1,000 nm. The nanoparticles are generally solid at 25° C. and are a combination of agent-carrier particles and emulsifiers. The membranes penetrate the nanoparticles...

20060024246 - Oral care compositions with film forming polymers: Oral care compositions comprising: a) an oral care active; and b) an acrylic film forming polymer. In various embodiments, such polymers comprise monomeric units such as acrylic acid, methacrylic acid, acrylates, and combinations thereof. In one embodiment, the film forming polymer comprises a copolymer of a first monomeric unit selected...

20060024247 - Oral care formulations comprising highly bioavailable coenzyme q-10 cyclodextrin complex: The present invention incorporates of a highly bioavailable coenzyme Q-10/cyclodextrin inclusion complex into oral care products, such as, toothpaste, mouth wash, chewing gum, breath mint, mouth spray, gels, and lozenges. The inclusion complex also is suitable for devices, such as dental loops, for delivering coenzyme Q-10 to the periodontum by...

20060024244 - Tooth whitening compositions and delivery systems therefor: Stain-removing oral compositions, such as gum compositions are herein provided. The compositions include an orally acceptable carrier and a stain-removing anionic surfactant. The surfactant includes a fatty acid salt having at least one hydroxyl functionality. The fatty acid salt may be a salt of ricinoleic acid, and may be combined...

20060024245 - Tooth whitening compositions and delivery systems therefor: Stain-removing oral compositions, such as gum compositions, are herein provided. The gum compositions include a film-forming agent, such as a fatty acid salt, in combination with an abrasive and a chelating agent. The fatty acid salt may be a salt derived from a hydroxy fatty acid. The chelating agent may...

20060024249 - Methods and compositions for bioengineering a tooth: This invention relates generally to methods and compositions for bioengineering tooth tissue, as well as methods of producing new tooth tissue in a subject....

20060024250 - High aspect ratio metal particles and methods for forming same: An electroless method of forming high aspect ratio metal particles includes the steps of mixing a metal or metal salt with at least one acid to form an acidified metal halide salt solution, and mixing the solution with a supersaturated sol to form a sol comprising solution. Metal cations provided...

20060024251 - Water-in-oil emulsion foundation comprising a polyol: The invention relates to a fluid foundation in the form of water-in-oil emulsion comprising an oil and an aqueous phase comprising a polyol, and optionally polymethyl methacrylate particles, the water+polyol/oil weight ratio being greater than or equal to 0.8. The foundation slides well on the skin and has a sensation...

20060024252 - Liquid stick antiperspirant: One embodiment of the invention described herein includes a method for improving stability of an antiperspirant. The method includes preparing a blend that comprises propylene glycol and dibenzylidene sorbitol; adding an antiperspirant active solid powder to the blend, to make an antiperspirant blend, in a concentration effective for making an...

20060024255 - Hair styling compositions comprising adhesive particles and non-adhesive particles: The invention relates to a hair styling composition comprising: an effective amount of at least one adhesive particle to provide a reshapable effect, an effective amount of at least one polymeric non-adhesive particle to impart at least one of the desirable properties and/or substantially maintain said reshapable effect relative to...

20060024254 - Personal care compositions: A concentrate including, by weight (a) 10% to 60%, preferably 25% to 35%, of a saturated fatty acid selected from stearic or palmitic acid, or mixtures thereof, in an adduct of an amidopropyldimethyl-2-hydroxyethyl ammonium halide, with substantially no free acid present, and (b) 40% to 90%, preferably 65% to 75%,...

20060024256 - Shampoo containing a gel network: Shampoo compositions comprise (a) from about 5% to about 50% of one or more detersive surfactants, by weight of the shampoo composition; (b) a dispersed gel network phase comprising, by weight of the shampoo composition, (i) at least about 0.05 % of one or more fatty amphiphiles; (ii) at least...

20060024253 - Use of a photocatalyst for the treatment of oily hair: The present invention relates to the use of a photocatalyst in hair compositions intended to decrease and/or to eliminate the unwanted organic compounds on the hair, in particular sebum. The invention relates in particular to the use of a photocatalyst in hair compositions intended to decrease and/or delay regressing of...

20060024260 - Cosmetic composition comprising a water-dispersible linear sulphonic polyester and a modified guar gum, methods employing this composition and uses: The present disclosure relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least one water-dispersible linear sulphonic polyester and at least one modified guar gum, methods employing this composition, and uses thereof....

20060024259 - Cosmetic composition comprising, in a non-fatty medium, at least one linear sulfonic polyester and at least one nonionic thickening polymer, processes using this composition and uses thereof: Disclosed herein is a cosmetic composition comprising, in a non-fatty cosmetically acceptable medium, at least one water-dispersible linear sulfonic polyester and at least one nonionic thickening polymer. Also disclosed herein are a method for shaping, holding, and/or fixing a hairstyle and a method for creating a water-resistant hairstyle by applying...

20060024261 - Cosmetic compositions comprising a linear sulfonic polyester and a polyurethane, processes using these compositions and uses thereof: The disclosure provides cosmetic compositions comprising, in a cosmetically acceptable medium, at least one water-dispersible linear sulfonic polyester and at least one thickening polyurethane in a particular ratio, processes using the cosmetic compositions, and uses of the cosmetic compositions for fixing hairstyles....

20060024262 - Aqueous composition and use thereof for paper production: The present invention relates to an aqueous composition comprising at least one finely divided filler and at least one water-soluble amphoteric copolymer, a process for the preparation of such a composition and its use as an additive in the production of paper, cardboard and board....

20060024263 - Polymer compositions: There is disclosed polymers and aqueous dispersions of them, the polymers containing specific copolymers which comprise at least four different ethylenically unsaturated monomers (such as 2-ethylhexyl acrylate, ethyl acrylate, methyl acrylate and styrene, and optionally (meth)acrylic acid, ethyl imidazolidone methacrylate, n-butyl acrylate n-dodecyl methacrylate and/or methyl methacrylate). Also described is...

20060024257 - Self-molding permanent agent and method for proceeding free-rod and free-band type permanent: The present invention relates to a self-molding permanent agent and a method for proceeding free-rod and free-band type permanent, more particularly to a self-molding permanent agent comprising (a) a reducing composition containing a reducing agent reducing a disulfide bond of cystine on the hair and a molding stimulant spontaneously molding...

20060024258 - Water-in-oil emulsion comprising a non-volatile non-silicone oil, cationic and nonionic surfactants, and an alkylmonoglycoside or alkylpolyglycoside: A hair composition in the form of an water-in-oil emulsion, containing at least one non-volatile non-silicone oil, at least one cationic surfactant, at least one nonionic surfactant, and from 0.01% to 10% by weight relative to the total weight of the composition of at least one material selected from (C12-30...

20060024265 - Methods and compositions for treatment of ion imbalances: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment...

20060024266 - Side-chain crystallizable polymers for medical applications: Inherently radiopaque side-chain crystallizable polymers (IRSCCP's) are useful in various medical applications. An example of a IRSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer, the heavy atoms being present in an amount that...

20060024264 - Antimicrobial copolymers and uses thereof: The present invention discloses random copolymers and methods of their use, including use of the copolymers as antimicrobial agents in pharmaceutical and non-pharmaceutical applications. The present invention also discloses compositions of the copolymers, and methods of preparing the copolymers....

20060024267 - Tnfr/opg-like molecules and uses thereof: The present invention provides novel TNFr/OPG-like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies, and methods for producing TNFr/OPG-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases with TNFr/OPG-like polypeptides....

20060024268 - Modulation of immunoglobulin production and atopic disorders: An IL-21 polypeptide or other IL-21 pathway agonist can be used to treat atopic disorders, e.g., asthma....

20060024269 - Use of il-28 and il-29 to treat cancer and autoimmune disorders: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as...

20060024270 - Compositions and methods for preventing or treating encephalitis with interferon: Compositions and methods are provided for preventing or treating a human suffering from a meningitis, encephalitis, meningo-encephalitis or encephalomyelitis caused by an arbovirus, comprising parenterally administering to the human an effective amount of interferon....

20060024271 - Treatments for viral infections using ifn cytokines and ribavirin, alone or in combination: A treatment or prophylaxis for viral infection using interferon (IFN) cytokines alone or in combination with ribavirin is provided. The treatments and prophylaxis allow for lowered dosages of IFNs, reduced pro-inflammatory responses, and delays the initiation time and reduced frequency of the IFN treatment required....

20060024272 - C-terminally truncated interferon: The invention described herein provides a C-terminally truncated interferon having enhanced biological activity and the polynucleotides encoding such interferon. Also provided are methods for producing and using such truncated interferon....

20060024274 - Retroviral vectors: A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence....

20060024273 - Target cell-specific adenoviral vectors containing e3 and methods of use thereof: The invention provides adenoviral vectors (preferably replication competent) comprising both an E3 sequence and at least one adenoviral gene under transcriptional control of a target cell-specific transcriptional response element. These vectors display significantly improved cytotoxicity, which is especially useful in the cancer context, in which selective destruction of target cells...

20060024278 - Methods and products related to the production of inner ear hair cells: The invention relates to the generation of inner ear sensory epithelial cells through the manipulation of the expression level or function of the genes and/or proteins involved in the retinoblastoma (Rb) pathway, particularly retinoblastoma family members, such as Rb1. Methods for generating inner ear sensory epithelial cells and for restoring...

20060024279 - Retroviral vectors: Retroviral vector particles having an RNA genome carrying sequences which provide in the DNA provirus at least one selected gene located within an intron in a transcription unit of the provirus, which transcription unit further comprises a polynucleotide response element responsive to a nucleus to cytoplasm transport factor such as...

20060024280 - Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis: The present invention provides cloned, genetically modified, endothelial cells, and the stem cells from which they are derived, which are produced by somatic cell nuclear transfer. The invention further provide novel therapeutic methods in which such cells are administered to a patient with tumors to inhibit and/or disrupt angiogenesis of...

20060024281 - Biological fertilizer compositions comprising poultry manure: The present invention provides biological fertilizer compositions that comprise yeast cells and poultry manure. The yeast cells of the invention have an enhanced ability to fix atmospheric nitrogen, decompose phosphorus minerals and compounds, decompose potassium minerals and compounds, decompose complex carbon compounds, overproduce growth factors, overproduce ATP, decompose undesirable chemicals,...

20060024282 - Biological fertilizer compositions comprising swine manure: The present invention provides biological fertilizer compositions that comprise yeast cells and swine manure. The yeast cells of the invention have an enhanced ability to fix atmospheric nitrogen, decompose phosphorus minerals and compounds, decompose potassium minerals and compounds, decompose complex carbon compounds, overproduce growth factors, overproduce ATP, decompose undesirable chemicals,...

20060024276 - Hybrid device for cell therapies: A device for receiving implanted biological material includes a porous outer wall defining an inner space, a fluid manifold assembly for selectively infusing at least one of immunosuppressive and growth factor media to said space, and a pump structure operatively coupled to the manifold assembly. The device may comprise an...

20060024277 - Method of skin care and/or treatment using extracts enriched in mitochondria: Methods for the prevention and treatment of skin aging arising from depletion of components of the mitochondrial membranes or the respiratory system using extracts rich in mitochondrial components in a dermatologically acceptable carrier that can be topically applied to the skin areas, including lips. In some embodiments, proteins such as...

20060024275 - Methods for use of mpl ligands with primitive human stem cells: Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations (CD34+Lin−, CD34+Thy-1+Lin−, and...

20060024283 - Red blood cells loaded with s-nitrosothiol and uses therefor: Red blood cells can be loaded with low molecular weight nitrosylating agents, such as S-nitrosothiols, to act as a delivery system for NO+ groups to tissues. Loaded red blood cells can be used in methods of therapy for conditions which are characterized by abnormal O2 metabolism of tissues, oxygen-related toxicity,...

20060024285 - Carcinogen detoxification composition and method: A pharmaceutical, food or cosmetic composition comprising a carrier and an effective amount of an active benzo(a)pyrene binding protein, whereby the protein is a SAM-dependent methyltransferase or a function-conservative variant or fragment thereof, having a SAM-binding domain specifically binding benzo(a)pyrene....

20060024284 - Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels: A method of reducing extracellular brain glutamate levels. The method comprises administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing blood glutamate levels thereby reducing extracellular brain glutamate levels....

20060024287 - Compositions and methods for modulating angiogenesis: The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to variants of tRNA synthetase fragments, or more preferably tryptophanyl tRNA synthetase fragments, or more preferably human tryptophanyl tRNA synthetase fragments....

20060024288 - Trna synthetase fragments: The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to multi-unit complexes of tRNA synthetase fragments and uses thereof; diverse multi-unit complexes including a tRNA synthetase fragment; compositions and methods for modulating angiogenesis; polynucleotides encoding tRNA synthetase fragments and...

20060024286 - Variants of trna synthetase fragments and uses thereof: The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to variants of tRNA synthetase fragments, or more preferably tryptophanyl tRNA synthetase fragments, or more preferably human tryptophanyl tRNA synthetase fragments....

20060024289 - Cleavage of vegf and vegf receptor by wild-type and mutant proteases: Disclosed herein are methods for creating and using mutein proteases with altered specificity for the target molecules they cleave. The invention further discloses methods of using wild-type and mutein granzyme B to target VEGFR proteins to treat diseases, such as cancer. Cleaving VEGFR at certain substrate sequences with wild-type and...

20060024294 - Compositions for prevention and treatment of infections caused by parasites in animals: The invention refers to anticoccidial compositions consisting mainly of yolk immunoglobulins derived from eggs of hens immunized with one or more Eimeria species. The invention refers also to the use of said anticoccidial compositions for prevention or treatment of coccidiosis. The administration of immunoglobulins, both in liquid as well as...

20060024293 - Human antibodies that bind human tnfalpha: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in...

20060024290 - Immunogenic lhrh compositions and methods relating thereto: The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns...

20060024292 - Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform: The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Gal2GlcNAc2Man3GlcNAc2 lacking fucose....

20060024291 - Protocadherin materials and methods: Polynucleotide sequences encoding novel cadherin-like polypeptides, designated protocadherins, and variants thereof are provided by the invention as well as methods and materials for the recombinant production of the same. Antibody substances specific for protocadherins are also disclosed as useful for modulating the natural binding and/or regulatory activities of the protocadherins....

20060024295 - Method for treating lupus: A method of treating lupus in a subject eligible for treatment is provided involving administering an effective amount of an antibody that binds to a B-cell surface marker to the subject to provide an initial exposure and a subsequent exposure to the antibody within certain dosing regimens and an article...

20060024299 - Human osteoclast derived cathepsin: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such...

20060024300 - Immunoglobulin variants and uses thereof: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases....

20060024298 - Optimized fc variants: The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants....

20060024296 - Therapeutic use of anti-cs1 antibodies: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including...

20060024297 - Tie complex binding proteins: Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity....

20060024301 - Prostate-specific polypeptides and fusion polypeptides thereof: Compositions and methods for the therapy and diagnosis of cancer, such as prostate cancer, are disclosed. Compositions may comprise one or more prostate-specific proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a prostate-specific protein, or a...

20060024302 - Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same: The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject....

20060024303 - Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells: Methods for targeting and prolonging association of a selected drug to the luminal surface of pulmonary vascular endothelium of an animal are provided wherein a selected drug is administered to an animal in combination with a non-internalizable antibody which binds to an antigen on the luminal surface of the pulmonary...

20060024304 - Immunoglobulins comprising predominantly a man5glcnac2 glycoform: The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Man5GlcNAc2....

20060024305 - Camp-regulated phosphoprotein for diagnostic and therapeutic use in neurodegenerative diseases: The present invention discloses a novel nucleic acid molecule encoding hTARPP. Further, the present invention discloses the differential expression of hTARPP in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or...

20060024308 - High affinity anti-tnf-alpha antibodies and method: An isolated human anti-TNF-α antibody, or antigen-binding portion thereof, containing at least one high-affinity VL or VH antibody chain that is effective, when substituted for the corresponding VL or VH chain of the anti-TNF-α scFv antibody having sequence SEQ ID NO: 1, to bind to human TNF-α with a Koff...

20060024307 - Media and method for treating pathological syndrome: A medicament based on antibodies contains an activated form of monoclonal, polyclonal, or natural antibodies to interferon in low or ultra-low doses prepared by multiple consecutive dilutions and exposure to external factors, preferably in accordance with homeopathic technology. In order to obtain antibodies, human or heterologous interferon alpha, beta, or...

20060024306 - Methods of treating and preventing colitis involving il-13 and nk-t cells: Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering...

20060024310 - Methods of treating tnfalpha-mediated tissue injury using anti-tnf antibodies and peptides: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of...

20060024309 - Methods of treating type i diabetes by blocking vegf-mediated activity: Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as the VEGF fusion protein trap of SEQ ID NO:2 capable of binding and blocking VEGF. The method of the invention may be combined with...

20060024313 - Agents that disrupt dimer formation in dpp-iv family of prolyl dipeptidases: The present invention relates to the finding that C-terminal loop and propeller loop and regions thereof of the DPP-IV family of prolyl dipeptidases play an important role in dimer formation. The present invention further provides purified polypeptides comprising an amino acid sequence that mimics conserved amino acids in at least...

20060024311 - Anti-viral activity of an anti-thymidine kinase monoclonal antibody: Monoclonal antibodies to thymidine kinase 1 are disclosed which are useful in methods of detecting, diagnosing, and treating viral infection....

20060024312 - Methods for enhancing learning and memory: Methods of maintaining or enhancing memory or learning in a mammal by activating the receptor tyrosine kinase muscle-specific kinase (MuSK) in the brain are disclosed. Also disclosed are methods of treating a disease or condition associated with memory loss or a neurological impairment by administering an effective amount of a...

20060024314 - Antibodies and cyclic peptides which bind cea (carcinoembryonic antigens) and their use as cancer therapeutics: The present invention relates to differentiation and tumorigenicity. The present invention more particularly relates to ligands which target CEA and CEACAM6 such that the adhesion, differentiation-Inhibitory activities and tumorigenic effects of Ig superfamily members, CEA and CEACAM6, can be reduced or blocked. More particularly, the present invention relates to CEA-binding...

20060024315 - Vascular targets for detecting, imaging and treating neoplasia or neovasculature: Methods of delivering an agent in a tissue-specific manner, by targeting annexin A1, a derivative of annexin A1, or a binding partner of annexin A1, are described. The methods can be used for detecting, imaging and/or treating neoplasia, angiogenesis or neovasculature, as well as for diagnostics and methods of assessing...

20060024317 - Chemical linkers and conjugates thereof: The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them....

20060024316 - Prostatic cancer vaccine: Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of at least one antigen over-represented in the prostate gland or an immunologically effective portion thereof; an expression system capable of generating in situ said...

20060024318 - Vaccination with immuno-isolated cells producing an immunomodulator: The present invention relates to immuno-protected encapsulated cells producing an immunomodulator, for example GM-CSF (granulocyte-macrophage colony stimulating factor). The cells of the invention are particularly well adapted for providing an active adjuvant or immunomodulator, for example in the context of immunisation in humans and animals. These cells can be used...

20060024320 - Attenuated pestiviruses: This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein ERNS is inactivated, methods of preparing, using and detecting these....

20060024319 - Murine calicivirus: i

20060024321 - Hiv antisense proteins: Disclosed is a novel HIV gene comprising a set of open reading frames encoded with the template as the plus strand of the proviral DNA, and located in the region of HIV-1 long terminal repeat. The genes encode a set of antisense proteins, (HAPS) as well as smaller proteins, related...

20060024323 - Active immunization using a siderophore receptor protein: The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are...

20060024322 - Novel prophylactics/remedies for immunopathy: A prophylactic/remedy for immunopathy for immunopathy comprising, as an active ingredient, modifications of Staphylococcal enterotoxin B (SEB) with substitution of at least one amino acid residues within the amino acid sequence of natural type SEB, or derivatives thereof, wherein the SEB modifications or derivatives thereof have inhibitory activity on T...

20060024324 - Malaria vaccine: A fusion protein, from P. falciparum Glutamate-rich protein(GLURP) genetically coupled to P. falciparum Merozoite surface protein 3 (MSP3) was produced in Lactococcus lactis as a secreted recombinant GLURP-MSP3 hybrid protein and experiments showed that the GLURP-part of the hybrid increased the overall antibody response. Immunizations with the hybrid protein consistently...

20060024326 - Biological compositions and methods for treatment of colorectal cancer: The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with colorectal cancer. The biological compositions can be used to retard the growth of colorectal cancer cells and/or prolonging the time of survival of the subject. The...

20060024325 - Biological compositions and methods for treatment of lung cancer: The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with lung cancer. The biological compositions can be used to retard the growth of lung cancer cells and/or prolonging the time of survival of the subject. The...

20060024327 - Composition for controlling blood sugar: The present invention is related to a composition for controlling blood sugar, which includes effective amount of blue algae and mulberry leaves. It can control blood sugar by means of the blue algae helping blood sugar metabolism and mulberry leaves blocking sugar decomposition and entering into blood. The present invention...

20060024328 - Potent immunostimulatory extracts from microalgae: Immunostimulatory compounds can be extracted from microalgae or algae using various procedures. The resulting preparations exhibit extremely potent immunostimulatory activity. The extraction of these immunostimulatory agents is dependent on the solvent used and the extraction temperature. These preparations are potentially useful as a botanical or pharmaceutical preparation to improve immune...

20060024329 - Recombinant live vaccine based on canine herpesvirus, in particular against carre's disease, rabies or the parainfluenza virus type 2.: Disclosed and claimed is a recombinant canine herpes virus (CHV). The recombinant CHV includes and expresses at least one heterologous nucleotide sequence encoding an antigen. The antigen can be canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus...

20060024330 - Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors: 8,9-Dihydroxydihydropyridopyrazine-1,6-diones and 8,9-dihydroxypyridopyrazine-1,6-diones are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the pyridopyrazinediones are of Formula (I): (I), wherein R1, R2, R3, R4 and R5 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention,...

20060024331 - Toxin compounds with enhanced membrane translocation characteristics: The present invention relates to a compound comprising a toxin linked to a translocator. Non-limiting examples of toxins of the present invention are botulimum toxin, butyricum toxin, tetani toxins and the light chains thereof. In some embodiments, the translocator of the present invention comprises a protein transduction domain....

20060024332 - Recombinant esat-6:cfp-10 fusion protein useful for specific diagnosis of tuberculosis: The fusion protein rESAT-6:CFP-10 is useful for differentiating infection of an animal with Mycobacterium bovis from exposure of the animal to other species of Mycobacteria, especially M. avium and M. avium subspecies paratuberculosis (Map). Cells stimulated with the fusion protein are capable of eliciting a variety of in vivo and...

20060024333 - Use of parasitic biological agents for prevention and control of allergic and other ige-mediated disorders: The present invention describes using, on a repetitive basis, a non-human colonizing helminth compound, in an amount sufficient to establish as needed a transitory helminth infection and or to simulate in a parasitic helminth infection with helminth excretory and secretory products (ESP), thereby having immunosuppressive effect against benign antigens and...

20060024334 - Immunotherapeutic methods and systems: Methods for desensitising an individual to a selected polypeptide antigen are provided. The methods entail administration of T cell epitope containing peptides from a polypeptide antigen in such a way as to establish a tolergeneic environment, that is, a state of hyporesponsiveness to the peptides. The selected polypeptide antigen is...

20060024336 - Ion binding compositions: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders,...

20060024335 - Oral compositions which mask the bitter taste of a bitter-tasting agent: An oral composition containing a bitter-tasting agent, such as for example, dextromethorphan, chlorhexidine, guaifenesin, pseudoephedrine, caffeine, peroxide, atorvastatin, aspirin, acetaminophen, diphenhydramine, doxylamine, sildenafil citrate, or loperamide, wherein the bitter taste ordinarily imparted by the bitter-tasting agent is abated or eliminated (i.e., masked) by an effective amount of a taste-receptor blocker,...

20060024338 - Cosmetic compositions incorporating vinyl acetate-ethylene polymers:

20060024342 - Customized retail point of sale dispensing methods: Methods for customizing products at a retail point of sale. A user interface is provided at the point of sale for selection of the desired product. Based upon the selection, ingredients are dispensed for making the personalized consumer product....

20060024340 - Encapsulated fluorescent whitening compositions for improved surface appearance: Microparticles containing an effective amount of at least one fluorescent whitening agent, wherein said fluorescent whitening agent is entrapped in a transparent or translucent matrix polymer that has been formed from a blend of monomers comprising a first monomer which is an ethylenically unsaturated ionic monomer and a second monomer...

20060024339 - Methods of managing the redness associated with a dermatological condition: A method is provided for managing redness of skin associated with a dermatological condition, the method comprising topically administering to the skin of a patient a pharmaceutical composition comprising an extract of goji berries. The pharmaceutical composition used in the methods of the invention can further comprise at least one...

20060024341 - Microemulsion composition and related method: A composition for oral administration to a subject as a microemulsion. The composition includes a surfactant having a hydrophilic-lipophilic balance of between about 12 and 16, a cosurfactant having a hydrophilic-lipophilic balance of between about 5 and 6, and an active ingredient, wherein the composition comprises a microemulsion when added...

20060024337 - Process for dissolving lipophilic compounds in aqueous solution with amphiphilic block copolymers, and cosmetic composition: The invention relates to a process for dissolving at least one lipophilic compound in at least one aqueous phase, characterized in that it comprises the step of associating the said lipophilic compound with an effective amount of at least one amphilic block copolymer comprising at least one ionic and/or at...

20060024343 - Animal deterrent for protecting plants: The invention provides materials, compositions, methods, and kits for deterring or repelling animals from eating plant materials. The invention relates to the use of particulate matter to deter animals from eating plant materials that are susceptible to grazing by animals. In exemplary embodiments, an adhesive is applied to target plant...

20060024344 - Capsicum shark repellent: This invention claims a use of Capsicum and Oleoresin capsicum (OC) as a chemical shark repellent. Alkyl chain , antioxidant phenolic group, and pungency properties of capsaicin contained in OC can exert a hostile reaction on lipit membrane of gills and on nonmedullated fibre nerves of body surface of sharks,...

20060024345 - Pediculicidal and ovacidal treatment compositions and methods for killing head lice and their eggs: The present invention relates to compositions and methods for administering compositions in solutions for killing adult lice and the ova comprising water, PVM/MA Decadiene crosspolymers, propylene glycol, a mixture of cetyl and stearyl alcohols, Ceteareth-20; stearalkonium chloride; benzyl alcohol; hexylene glycol; pentylene glycol, isopropyl alcohol; a mixture of spinosyn A...

20060024347 - Bioactive peptide coatings: The invention provides a coating and a method for coating medical devices with synthetic heparin-binding growth factor analogs, the coating and method including at least one heparin-binding growth factor analog with a region of amino acid residues binding a heparin-binding growth factor receptor, a hydrophobic linker region and a heparin-binding...

20060024348 - Chemically bonded biomaterial element with tailored properties: where λ is the distance between filler particles of mean size d, and VF is the volume content of non-reacted cement and added filler, and where λ≦10 μm. The invention also relates to a device in connection with the preparation of a chemically bonded biomaterial element according to the invention....

20060024349 - Method for creating a separation of posterior cortical vitreous from the retina of the eye: A method is disclosed for creating a separation of posterior cortical vitreous from the retina of the eye. The method includes the step of introducing plasmin into the vitreous humor of the eye. The plasmin may be introduced either by injection or through a sustained release device. Optionally, other enzymes,...

20060024346 - Stabilization of biologically active proteins with mixtures of polysaccharides and amino acid based compounds: The invention provides heat stable aqueous solutions or gels comprising a biologically active protein and a stabilizing effective amount of a mixture of a polysaccharide and an amino acid based compound. The invention also discloses stabilized solutions or gels suitable for use in an implantable drug delivery device at body...

20060024350 - Biodegradable ocular devices, methods and systems: The invention provides implantable medical devices that are fabricated of biodegradable materials for delivery of bioactive agent to limited access regions of a patient's body, such as the eye. The invention further provides methods of treatment utilizing the devices....

20060024351 - Hydrating breath freshening beverage compositions and method therefor: A hydrating beverage comprises an effective amount of at least one breath freshening additive in a suitable amount of water to hydrate a person to prevent halitosis and bad breath when the hydrating beverage is consumed by the person and distributed to the mouth, the throat and the stomach of...

20060024352 - Phytosterol nutritional supplements: The invention provides a nutritional supplement which includes phytosterol to facilitate reduction of cholesterol. The nutritional supplement may be a swallowable tablet, chewable tablet, sachet, capsule or suspension. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing...

20060024354 - Confectionary product containing functional ingredients: A gum, lollipop and lozenge having at least two separate components, with at least one of such components containing amounts of herbal, medicinal and/or mineral elements or combinations thereof....

20060024353 - Novel porous film-forming granules, process for their preparation and application in the film coating of tablets and sweets: A film forming composition and a method for its use. The composition is in the form of somewhat porous granules and has a bulk density of less than about 0.5 g/cm3. The composition contains a film-forming polymer, a plasticizer and an inert filler....

20060024356 - Canine osteoarthritis diet formulation: Dietary formulations and methods for treating, preventing or delay onset of osteoarthritis in canines and other animals are disclosed. The formulations are enriched in n-3 fatty acids and limited in n-6 fatty acids....

20060024355 - Stabilized pancreas product: The present invention provides stabilized pancreas products useful, for example, as an animal feed additives. The invention also provides for feed additives and feed rations comprising a stabilized pancreas product. Further, the invention provides for methods of making stabilized pancreas products. The present invention also provides for methods of supplementing...

20060024357 - Wound healing polymer compositions and methods for use thereof: The present invention provides bioactive polymer compositions that can be formulated to release a wound healing agent at a controlled rate by adjusting the various components of the composition. The composition can be used in an external wound dressing, as a polymer implant for delivery of the wound healing agent...

20060024358 - Multi-reservoir device for transdermal drug delivery and sensing: Devices and methods are provided for transdermal administration of a pharmaceutical agent to a patient in need thereof. The device includes a substrate, a plurality of discrete reservoirs in the substrate, one or more pharmaceutical agents stored in the reservoirs, discrete reservoir caps that prevent the pharmaceutical agent from passing...

20060024359 - Drug delivery system and method: A method for delivering a therapeutic agent to a predetermined location in a host is disclosed, wherein a liposome-encapsulated therapeutic agent is administered to the host, and an electrical field which encompasses a predetermined region within the host is established, such that as the liposome-encapsulated agent is exposed to the...

20060024360 - Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof: The present invention provides compositions that comprise alpha-tocopheryl succinate or its analogue or salt and methods for preparing and using such compositions....

20060024362 - Composition comprising a benzimidazole and process for its manufacture: The invention provides new benzimidazole compositions, comprising: (a) a core containing said benzimidazole active ingredient; (b) an intermediate layer; and (c) an enteric layer; said core being substantially free of binder. The invention also provides a process for manufacturing the composition of the invention....

20060024363 - Directly compressible formulations of azithromycin: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed...

20060024364 - Directly compressible formulations of azithromycin: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed...

20060024361 - Disintegrant assisted controlled release technology: A disintegrant assisted controlled release device is disclosed. The device is a combination of a swelling disintegrant or super-disintegrant and water insoluble polymer or water soluble polymer, or both, and one or more water soluble or water insoluble active pharmaceutical ingredient(s). The said device is stabilized by a humectant or...

20060024367 - Controlled release alpha lipoic acid formulation with an inositol compound: A biphasic formulation of an inositol compound and lipoic acid for oral administration is disclosed. The lipoic acid and the inositol compound are combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation...

20060024366 - Modified release compositions of milnacipran: A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total...

20060024365 - Novel dosage form: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active...

20060024368 - Compressed composite delivery system for release-rate modulation of bioactives: The invention is a delivery system comprising a first outer zone which partially surrounds an inner core, a second outer zone which also partially surrounds the core, and the outer zones together form a continuous heterogeneous layer fully surrounding the core. The delivery system is particularly suitable for orally administered...

20060024369 - Chlorine dioxide releasing composite article: A composite article that includes a ClO2-producing material integrated into an organic matrix and methods of using the same are described. The organic matrix of the composite article is formable at a temperature under about 150° C., permits contact between an activating stimulus (e.g., water vapor and/or electromagnetic energy) and...

20060024370 - Modafinil oral lyophilizate: The invention concerns an oral lyophilizate comprising modafinil particles having a median diameter of about 10 to about 1000 μm in association with an appropriate amount of at least one excipient selected from the group consisting of fatty acid esters of glycerol, cyclic oligosaccharides, sweeteners or mixtures thereof....

20060024371 - Biocompatible material composition adaptable to diverse therapeutic indications: A biocompatible material genus serves as the foundation for multiple material composition species, each adapted to a specific therapeutic indication....

20060024373 - Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants: The present invention concerns universal biocompatible matrices comprising cross-linked hyaluronic acid-laminin gels useful for clinical applications including as implants, for tissue engineering as well as in biotechnology. The gel matrices according to the present invention may be used clinically either per se or as a cell bearing implant, e.g., stem...

20060024372 - High viscosity antibacterials: An antibacterial fluid may be applied to a tubular medical cannula for access to a patient. The fluid comprises a typically metabolizable antibacterial formulation having a viscosity preferably greater than 150,000 cp. The cannula may then be inserted into the patient with an increased lubricity for a reduction of pain,...

20060024377 - Composite materials for controlled release of water soluble products: Composite materials comprising a water-soluble compound adsorbed onto a basic inorganic material and a bio-degradable polymer which yields acidic degradation products, methods of producing same, and methods of use thereof are described, wherein the composite materials are designed so as to provide controlled release of the water soluble molecule....

20060024378 - Magnetically responsive carbon nano-structures for transporting biologically active substances, and methods relating thereto: This invention is directed to a composition for medicinal transportation in a biological fluid. The carrier composition is a single or multi-walled nanostructure, open or closed at either end, having a non-metallic ferromagnetic component (A), a metallic ferromagnetic component (B), and a carbon component (C), where the atomic ratio of...

20060024376 - Methods and compositions for reducing toxicity associated with leflunomide treatment: The invention relates to methods and compositions useful in alleviating or reducing toxicity associated with leflunomide administration without reducing its bioactivity, e.g., without reducing its immunosuppressive activity, that is, utilizing a bioavailable pyrimidine compound to ameloriate the toxic effects caused by leflunomide compounds....

20060024374 - Pharmaceutical compositions suitable for the treatment of ophthalmic diseases: Pharmaceutical compositions for the treatment of ophthalmic diseases, suitable for topical ocular administration and for systemic administration, comprising solid lipid nanoparticles (SLNs) with a mean diameter comprised between 50 and 400 nm wherein, within said nanoparticles, a pharmacologically active substance for the specific ophthalmic treatment is incorporated....

20060024375 - Powders coated with specific lipoamino acid composition and cosmetics containing the same: There is provided a coated powder having a high skin care effect and a high anti-aging effect. The powder which can be used in cosmetics is coated with a mixture (lipoamino acid composition) comprising N-acyl derivatives (also including the form of a salt) of (1) at least one amino acid...

20060024379 - Protein microspheres having injectable properties at high concentrations: The present invention relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in...

20060024380 - Chemical cleaning of biological material: The invention is directed to collagenous tissues which have been treated to remove non-collagenous components such as cells, cellular debris, and other extracellular matrix components, such as proteoglycans and glycosaminoglycans, normally found in native tissues. Treatment of the tissue with alkali, chelating agents, acids and salts removes non-collagenous components from...

20060024381 - Composition comprising particulate zinc material with a high relative zinc lability: The present invention relates to a composition comprising an effective amount of a particulate zinc material, an effective amount of a surfactant including a surfactant with an anionic functional group wherein the particulate zinc material has a relative zinc lability of greater than about 15% and wherein the composition comprises...

20060024382 - Platinum nanocolloid solution, process for producing the same and drink containing platinum nanocolloid: A nanocolloidal platinum dispersion comprising nanocolloidal platinum and a polyacrylic acid salt, the nanocolloidal platinum having an average particle size of 1-5 nm, 90% or more of the nanocolloidal platinum having a particle size in a range of 0.1-10 nm, its production method, and a drink containing such a nanocolloidal...

20060024383 - Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses: A composition is provided which contains policosanol and chromium and/or chromium salts and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases,...

20060024384 - Compositions and methods for nutrition supplementation: The present invention relates to compositions, that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment, comprise vitamin B6, vitamin B9, vitamin B12, calcium, vitamin D3, magnesium, and boron, and methods for using these compositions for nutritional supplementation in order to prevent, treat...

20060024386 - Herbal extract with antiviral properties: Herbal extract compositions designed and used for the clinical management of HIV/AIDS, especially in sub-Saharan Africa and Nigeria. Herbal extract compositions are any one of or any combination of Ficus exaspirata, Ficus asperifolia, Ficus sur and Sida acuta/Sida corymbosa. Methods of treating HIV/AIDS infection with herbal extract compositions are also...

20060024385 - Metabolic capacity enhancing compositions and methods for use in a mammal: Metabolic energy capacity enhancing compositions and methods for reducing oxidative stress and improving vitality in a mammal are disclosed. A composition for increasing metabolic energy capacity may be in a palatable liquid formulation or a solid dosage form and typically includes an anti-oxidant containing phytonectar and an energy catalyst. An...

20060024387 - Methods and compositions for increasing milk production in animals: The invention is related to methods and compositions for increasing milk production in animals using a saponin containing composition. In an embodiment, the invention is a method for increasing milk production of an animal comprising administering an initiation dose of a saponin-containing composition to the animal within five days before...

20060024388 - Plant derived or derivable material with appetite suppressing activity: A method of suppressing or curbing appetite and treating or preventing obesity comprising administering to a human or other mammal in need of such treatment an effective amount of plant material derived or derivable from plants of the genera Stapelia and Orbea....

20060024389 - Plant derived or derivable material with appetite suppressing activity: A method of suppressing or curbing appetite and treating or preventing obesity comprising administering to a human or other mammal in need of such treatment an effective amount of plant material derived or derivable from plants of the genera Stapelia and Orbea....

20060024390 - Palm fiber-based dietary supplements: The present invention relates to palm fiber-based dietary supplements. Specifically, the inventions relates to compositions of palm trunk fiber with high antioxidant capability and SOD-like activity, and their uses. The invention further provides for methods of preventing or treating disorders in a subject caused by reactive oxygen chemical species....

20060024391 - Dietary nutritional suppliments for persons smoking tobacco products: A dietary nutritional supplement is designed specifically to address the needs of tobacco users, in particular smokers. The nutritional supplement for smokers contains effective amounts of vitamin B complex, vitamin B12 (Cobalamin), Vitamin B3 (Niacin), vitamin C (Ascorbic acid), L-cysteine, L-methionine, co-enzyme Q10, milk thistle, ginko, ginseng, selenium, yerb santa,...

20060024392 - Compositions and methods for enhancing the effectiveness of a chemotherapeutic agent: This invention relates to food components such as phytochemicals including anthocyanins that can enhance the effectiveness of a chemotherapeutic agent in treating a cell proliferative disorder and/or reduce chemotherapy-induced side effects during treatment of a cell proliferative disorder....

20060024393 - Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases: An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a...

20060024394 - Cancer cell growth inhibition by black bean (phaseolus vulgaris l) extracts: A group of phytochemical compounds extracted from whole germinated or not germinated black beans (Phaseolus vulgaris L) and/or their dry milled fractions such as seed coats or hulls and cotyledons is described. These phytochemicals are classified as phenolics, such as polyphenols, flavonoids, coumarins, and tannins, triterpenes such as saponins, phytosterols...

20060024395 - Enhanced wound healing method and composition: A composition extracted from nut husks including a method of forming the composition, where the composition is useful in healing wounds. The method includes collecting pecan husks, pressing the pecan husks thereby expressing fluid from the husks, and collecting the expressed fluid. The extraction process is conducted in an inert...

20060024396 - Method of treating diabetes and obesity using carbohydrate absorption inhibitors: This invention provides carbohydrate absorption inhibitor derived from evening primrose seed which is significantly effective to prevent and cure diabetes mellitus and prevent obesity, and the manufacturing method of the same. Carbohydrate absorption inhibitor in this invention is characterized that the effective component is an alcohol extract of evening primrose...

20060024397 - Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation: The present invention describes food supplements that contain one or more fruit extracts useful for pain relief and anti-inflammation. The food supplements may be used to inhibit inflammation mediated by cyclooxygenase and more particularly by cyclooxygenase-2....